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ABSTRACT 
The design of novel materials with significant biological properties is a main target in drug design research. 
Chromene compounds represent an interesting medicinal scaffold in drug replacement systems. This report illus-
trates a successful synthesis and characterization of two novel series of chromene compounds using multi-compo-
nent reactions. The synthesis of the first example of azo chromophores containing chromene moieties has also 
been established using the same methodology. The antimicrobial activity of the new molecules has been tested 
against seven human pathogens including two Gm+ve, two Gm-ve bacteria, and four fungi, and the results of the 
inhibition zones with minimum inhibitory concentrations were reported as compared to reference drugs. All the 
designed compounds showed significant potent antimicrobial activities, among of them, four potent compounds 
4b, 4c, 13e, and 13i showed promising MIC from 0.007 to 3.9 µg/mL. In addition, antiproliferative analysis against 
three target cell lines was examined for the novel compounds. Compounds 4a, 4b, 4c, and 7c possessed significant 
antiproliferative activity against three cell lines with an IC50 of 0.3 to 2 µg/mL. Apoptotic analysis was performed 
for the most potent compounds via caspase enzyme activity assays as a potential mechanism for their antiprolifer-
ative effects. Finally, the computational 2D QSAR and docking simulations were accomplished for structure-ac-
tivity relationship analyses.  
 
Keywords: chromene compounds, chromene azo dyes, antitumor activity, biological applications, 2D QSAR and 
docking simulations 
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INTRODUCTION 
The vast majority of health problems fac-
ing the world’s population at the present time 
are cancer and infectious diseases (Trinchieri, 
2015). Cancer is one of the most frequent 
causes of death in developing countries, and 
the identification of new therapies is an area 
of ongoing importance in biomedical research 
(Higginson and Costantini, 2008; Varmus, 
2006). Liver, colon, breast, and melanoma 
cancers are most common in developed and 
underdeveloped countries. Therefore, there is 
an urgent need to search for new specific an-
ticancer agents (Settimo et al., 1998; Sondhi 
et al., 2010). For this purpose, chemotherapy 
is the most commonly used treatment world-
wide to cure various types of cancers (Isakoff, 
2010). Currently, combination chemotherapy 
with different mechanisms of action is one of 
the methods that are being adopted to treat 
cancer (Pritchard et al., 2013). 
Meanwhile, bacterial infections remain a 
serious threat to human lives because of its 
emerging resistance to existing antibiotics, 
which is another increasing public health 
problem. Consequently, there is a vital need 
for the development of new antimicrobial 
agents with potent activity against drug re-
sistant microorganisms (Coates et al., 2002). 
The drug discovery research of antimicrobial 
agents, accompanied by clinical development, 
has largely been conducted by many pharma-
ceutical companies (Bush, 2004) in order to 
develop new safer, potent, and resistance-free 
antimicrobial drugs (Devasahayam et al., 
2010). For this reason, the discovery of novel 
anticancer and antimicrobial agents is im-
portant and timely endeavor for public health. 
Oxygen atom-containing heterocyclic 
molecules are one of the main targets in drug 
design research. In particular, chromene com-
pounds are well known as important compo-
nents either in biologically active synthetic or 
natural compounds (Devakaram et al., 2012; 
Iriti and Faoro, 2010; Juan et al., 2001; Ren et 
al., 2011). Certain natural and synthetic 
chromene analogues have shown a diversity 
of interesting properties over the years (Ali et 
al., 2015; Cai et al., 2006; Cheng et al., 2003; 
Jain et al., 2009; Kamdar et al., 2010; 
Kemnitzer et al., 2008; Mladenovic et al., 
2011; Mori et al., 2006; Thareja et al., 2010). 
Some of these molecules exhibited significant 
effects as antitumor (Cai et al., 2006; 
Kemnitzer et al., 2008), antivascular 
(Gourdeau et al., 2004), antimicrobial (Ali et 
al., 2015), antioxidant (Mladenovic et al., 
2011), antifungal (Thareja et al., 2010), anti-
coagulant (Jain et al., 2009), anti-HIV (Park 
et al., 2008) and anti-inflammatory (Kamdar 
et al., 2010) activities. The most important 
character of these molecules is the lipophilic 
character of the benzopyran moieties which 
facilitates their delivery into the cell mem-
brane (Nicolaou et al., 2000). 
Chromene compounds have been synthe-
sized using various approaches, including 
multi-component reactions (MCRs) 
(Boominathan et al., 2011; Elinson et al., 
2010; Kirilmis et al., 2008; Shafiei-Haghighi, 
2011), heterogeneous catalytic methods 
(Mehrabi and Kazemi-Mireki, 2011; Yadav et 
al., 2007), electro-catalytic process (Makarem 
et al., 2008), green synthesis routes using 
aqueous media (Kumar et al., 2009; Murthy et 
al., 2010), microwave (Sangani et al., 2012, 
2013) and ultrasound techniques (Safari and 
Javadian, 2015). In addition, chromene com-
pounds seem to be interesting precursors for 
the preparation of azo dyes, either as amine or 
coupler molecules. Azo chromophores syn-
thesis and developments is a very rich area in 
current literature (Abd-El-Aziz and Afifi, 
2006; Shawali and Samy, 2015), however, 
this topic still inspires many researchers due 
to the new possibilities of applications that 
this class of compounds may possess (Abd-
El-Aziz and Afifi, 2006; Shawali and Samy, 
2015; Wainwright, 2008; Zheng et al., 2010). 
Due to the high biological activity of the 
chromene compounds as well as the interest-
ing optical properties of azo molecules, com-
bination of these molecules allows the con-
struction of new materials that expected to re-
veal new chemical, physical as well as biolog-
ical properties. 
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Meanwhile, it is well known that the most 
important aspect of activity of 4-Aryl-4H-
chromenes is the apoptotic modulation effect 
by cell- and caspase-based protocols on can-
cer cells, leading to growth inhibition and 
hence cell death (Kemnitzer et al., 2004, 
2005, 2007). For instance, Kemnitzer et al. 
(2008) have reported 4-aryl-4H-chromenes as 
potent inducers of apoptosis through tubulin 
inhibition. They indicated that the 4-position 
is quite critical for the structure-activity rela-
tionship of such derivatives. 
In view of the above mentioned benefits 
and in continuation of our previous work in 
development synthesis of polyfunctional-sub-
stituted heterocyclic compounds with poten-
tial biological activity (Abd-El-Aziz et al., 
2016; Ahmed et al., 2016), we report here the 
utility of the 3- and 5-aminonaphthol compo-
nents as building blocks with different physi-
cochemical properties for the synthesis of 2,7-
diamino-4-phenyl-4H-benzo[h]chromene-3-
carbonitrile (4a-i) and 3,5-diamino-1-phenyl-
1H-benzo[f]chromene-2-carbonitrile (7a-e). 
In addition, the present study shows the syn-
thesis of 2-amino-7-hydroxy-4-phenyl-6-
(phenyldiazenyl)-4H-chromene-3-carboni-
trile (13a-k) compounds as a first example of 
azo dye incorporating chromene derivatives 
with the purpose of investigating their possi-
ble biological and cytotoxic activities. Struc-
tures of the novel molecules were elucidated 
on the basis of IR, 1H-, 13C- NMR and MS, 
and their UV-vis behaviors were also exam-
ined. 
 
Study rationale 
In continuation to our previous work, lip-
ophilic parameters were found to control the 
activity of phenyl chromene carbonitrile de-
rivatives (Du et al., 2011; Gellert et al., 1976; 
Widelski et al., 2009). Accordingly, in our 
synthesis we consider the incorporation of 
fused aromatic systems in this scaffold to 
study the effect of the activity by using naph-
thyl amine precursors. In addition, we also 
demonstrated the formation of chromene azo 
dye via the formation of diazonium salt and 
its coupling with resorcinol to produce the 
stable azo dye. This reaction is followed by 
building the chromene scaffold with more po-
lar surface area and lipophilic characters in 
order to increase the surface area in an effort 
to reach the maximum logP value as an indi-
cator of lipophilicity (Figure 1).
 
 
Figure 1: Target scaf-
fold with correspond-
ing novel series com-
pounds appearing the 
mapping of physico-
chemical properties to 
biological activity 
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EXPERIMENTAL WORK  
 Chemistry 
Materials & Characterization 
All chemicals were available from Sigma-
Aldrich Chemical Co. and were used without 
purification. Solvents were HPLC grade and 
were used without further purification, with 
the exception of ethanol, which was distilled 
prior to use. 2,7-amino-4-aryl-3-cyano-4H-
chromene and 2-amino-4-aryl-7-hydroxy-3-
cyano-4H-chromene series were synthesized 
according to a previous report (Voskressen-
sky et al., 2014). The progress of the reactions 
was monitored using thin layer chromatog-
raphy (TLC) on Merck silica gel 60 F254 
plates. 1H and 13C NMR spectra were rec-
orded at 400 and 125 MHz, respectively, on a 
Gemini 200 NMR spectrometer, with chemi-
cal shifts calculated in Hz, referenced to sol-
vent residues. Infrared spectra were recorded 
on a Bomem, Hartmann & Braun FT-IR spec-
trophotometer as KBr pellets. Mass spectra 
were measured using a Shimadzu GC/MS-
QP5050A spectrometer (Shimadzu, Japan). 
UV-vis measurements were performed on 
Carry 100.  
Preparation of 3,5-diamino-4-aryl-4H-ben-
zochromene-2-carbonitriles (4a-i) 
A mixture of 3-amino-2-naphthol (10 
mmol), malononitrile (10 mmol) and aromatic 
aldehyde (10 mmol) were dissolved in EtOH 
(15 ml), then piperidine (0.5 ml) was added. 
The mixture was refluxed for 2-4 hours until 
complete precipitation occurred. The isolated 
precipitate was filtered, washed with ethanol 
and recrystallized from ethanol. Characteriza-
tion of the new compounds was achieved us-
ing NMR, FTIR and mass spectrometry. 
 
3,5-diamino-1-(4-fluorophenyl)-1H-
benzo[f]chromene-2-carbonitrile (4a) 
Colorless crystals from ethanol (67 % 
yield), mp 193 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2190 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 5.20 
(s, 1H, H-4), 5.45 (s, 2H, NH2-10) 6.85 (s, 2H, 
NH2-2), 6.91 (s, 1H, Ar-H), 6.97-7.04 (m, 3H, 
Ar-H), 7.13-7.17 (m, 3H, Ar-H), 7.47 (d, J= 
9.0 Hz, 1H, Ar-H), 7.53 (d, J= 9.0 Hz, 1H, Ar-
H). 13C NMR (125 MHz) (DMSO-d6) δ 
(ppm): 37.41(C-4), 57.98 (C-3), 106.85 (C-9), 
115.52 (Ar-CH), 115.88 (C-4a), 120.37 (CN), 
122.08 (C-5), 122.64 (C-4b), 123.21 (C-6) 
124.89 (C-7), 125.66 (C-8), 128.69 (Ar-CH), 
132.07 (C-8a), 136.29 (C-10), 138.05 (Ar-C), 
141.83 (C-10a), 159.79 (C-2), 161.99 (Ar-C). 
19F NMR (DMSO-d6) δ (ppm): -116.11 (Ar-
F). MS m\z (%): 331 (M+, 20.5) with base 
peak at 237. 
 
3,5-diamino-1-(4-chlorophenyl)-1H-
benzo[f]chromene-2-carbonitrile(4b) 
Colorless crystals from ethanol (73 % 
yield), mp 187 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2195 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 5.35 
(s, 1H, H-4), 5.66 (s, 2H, NH2-10) 7.06-7.13 
(m, 4H, NH2-2 & Ar-H), 7.23-7.29 (m, 3H, 
Ar-H), 7.35 (d, J= 9.0 Hz, 2H, Ar-H), 7.60 (d, 
J= 9.0 Hz, 1H, Ar-H), 7.64 (d, J= 9.0 Hz, 1H, 
Ar-H). 13C NMR (125 MHz) (DMSO-d6) δ 
(ppm): 37.46 (C-4), 57.78 (C-3), 107.11 (C-
9), 115.57 (C-4a), 120.43 (CN), 122.22 (C-5), 
122.72 (C-6), 123.19 (C-7) 124.98 (C-8), 
125.74 (C-4b), 128.71 (Ar-CH), 131.23 (C-
8a), 132.13 (Ar-C), 136.30 (C-10), 138.19 
(Ar-C), 144.54 (C-10a), 159.89 (C-2). MS 
m\z (%): 347 (M+, 19.8) with base peak at 236 
(100). 
 
3,5-diamino-1-(p-tolyl)-1H-
benzo[f]chromene-2-carbonitrile(4c) 
Colorless crystals from ethanol (64 % 
yield), mp 180 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2198 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 2.12 
(s, 3H, CH3), 5.09 (s, 1H, H-4), 5.43 (s, 2H, 
NH2-10) 6.79 (s, 2H, Ar-H), 6.90 (s, 1H, Ar-
H), 6.98 (br s, 5H, NH2-2 & Ar-H), 7.13 (t, J 
= 9.0 Hz, 1H, Ar-H), 7.45 (d, J = 9.0 Hz, 1H, 
Ar-H), 7.52 (d, J = 9.0 Hz, 1H, Ar-H). 13C 
NMR (125 MHz) (DMSO-d6) δ (ppm): 20.58 
(CH3), 37.98 (C-4), 58.28 (C-3), 106.74 (C-
9), 116.17 (C-4a), 120.54 (CN), 122.02 (C-5), 
122.82 (C-6), 123.33 (C-7), 124.83 (Ar-C), 
125.64 (C-8), 126.81 (Ar-CH), 129.24 (Ar-
CH), 132.08 (C-4b), 135.66 (C-8a), 136.28 
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(C-10), 138.09 (Ar-C), 142.71 (C-10a), 
159.71 (C-2). MS m\z (%): 327 (M+, 15.9) 
with base peak at 236 (100) 
 
3,5-diamino-1-(4-methoxy-phenyl)-1H-
benzo[f]chromene-2-carbonitrile(4d) 
Colorless crystals from ethanol (60 % 
yield), mp 183 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2185 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 3.67 
(s, 3H, CH3), 5.17 (s, 1H, H-4), 5.51 (s, 2H, 
NH2-10), 6.82 (d, J = 9.0 Hz, 2H, Ar-H), 6.87 
(s, 2H, NH2-2), 6.98 (br. s, 1H, Ar-H), 7.05-
7.12 (m, 3H, Ar-H), 7.22 (t, J = 9.0 Hz, 1H, 
Ar-H), 7.54 (d, J= 9.0 Hz, 1H, Ar-H), 7.63 (d, 
J= 9.0 Hz, 1H, Ar-H). 13C NMR (125 MHz) 
(DMSO-d6) δ (ppm): 37.50 (C-4), 55.60 
(OCH3), 58.34 (C-3), 107.00 (C-9), 116.19 
(C-4a), 120.40 (CN), 122.09 (C-5), 122.87 
(C-6), 123.34 (C-7) 124.88 (C-8), 125.64 (C-
4b), 126.89 (C-8a), 128.74 (Ar-CH), 138.17 
(C-10), 146.46 (C-10a), 159.81 (Ar-C), 
160.07 (C-2). MS m\z (%): 343 (M+, 13.95) 
with base peak at 186 (100).  
 
3,5-Diamino-1-(2,4-dichloro-phenyl)-1H-
benzo[f]chromene-2-carbonitrile (4e) 
Colorless crystals from ethanol (69 % 
yield), mp 278 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2200 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 5.57 
(s, 2H, NH2-10), 5.67 (s, 1H, H-4), 6.99 (d, J= 
9.0 Hz, 1H, Ar-H), 7.05 (br. s, 3H, Ar-H & 
NH2-2), 7.10 (d, J= 9.0 Hz, 1H, Ar-H), 7.19-
7.23 (m, 2H, Ar-H), 7.38 (d, J= 9.0 Hz, 1H, 
Ar-H), 7.56 (d, J= 9.0 Hz, 1H, Ar-H), 7.59 (s, 
1H, Ar-H). 13C NMR (125 MHz) (DMSO-d6) 
δ (ppm): 35.29 (C-4), 56.63 (C-3), 107.82 (C-
9), 115.05 (C-4a), 120.17 (CN), 122.61 (C-5), 
122.94 (C-6), 123.06 (C-4b), 125.48 (C-7) 
126.34 (C-8), 128.90 (Ar-CH), 129.21 (Ar-
CH), 131.57 (Ar-CH), 132.22 (C-8a), 132.47 
(Ar-C), 136.64 (C-10), 138.88 (Ar-C), 142.16 
(C-10a), 160.37 (C-2). 19F NMR (DMSO-d6) 
δ (ppm): -111.92, -115.30 (Ar-F). MS m\z 
(%): 382 (M+, 12.5) with base peak at 237. 
 
3,5-Diamino-1-(2,4-difluoro-phenyl)-1H-
benzo[f]chromene-2-carbonitrile (4f) 
Colorless crystals from ethanol (69 % 
yield), mp 282 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2202 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 5.49 
(s, 1H, H-4), 5.54 (s, 2H, NH2-10), 6.95 (t, J= 
9.0 Hz, 1H, Ar-H), 7.03 (br. s, 3H, Ar-H & 
NH2-2), 7.10 (t, J= 9.0 Hz, 1H, Ar-H), 7.18-
7.22 (m, 3H, Ar-H), 7.50-7.56 (m, 2H, Ar-H). 
13C NMR (125 MHz) (DMSO-d6) δ (ppm): 
32.69 (C-4), 56.57 (C-3), 104.50 (Ar-CH), 
107.61 (C-9), 114.66 (C-4a), 120.59 (CN), 
122.69 (C-6), 122.79 (C-7), 123.04 (C-8), 
125.38 (C-5) 126.29 (Ar-CH), 128.74 (C-4b), 
128.88 (C-8a), 131.21 (Ar-C), 132.46 (Ar-
CH), 136.67 (C-10), 138.89 (C-10a), 158.55 
(Ar-C), 160.32 (Ar-C), 160.64 (C-2). 19F 
NMR (DMSO-d6) δ (ppm): -111.92, -115.30 
(Ar-F). MS m\z (%): 349 (M+, 18.9) with base 
peak at 237. 
 
3,5-Diamino-1-(2-fluoro-3-trifluorome-
thyl-phenyl)-1H-benzo[f]chromene-2- 
carbonitrile (4g) 
Colorless crystals from ethanol (64 % 
yield), mp 202 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2210 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 5.57 
(s, 2H, NH2-10), 5.63 (s, 1H, H-4), 7.05 (s, 
2H, NH2-2), 7.11 (br. s, 3H, Ar-H), 7.21-7.29 
(m, 2H, Ar-H), 7.51-7.57 (m, 4H, Ar-H). 13C 
NMR (125 MHz) (DMSO-d6) δ (ppm): 
33.31(C-4), 56.06 (C-3), 107.86 (C-9), 114.12 
(C-F3), 120.44 (C-4a), 122.61 (CN), 122.98 
(C-5), 124.45 (Ar-C), 125.47 (C-6) 125.76 
(C-7), 126.37 (Ar-CH & C-8), 132.49 (Ar-
CH), 133.97 (C-4b), 134.09 (C-8a), 135.05 
(Ar-H), 136.70 (C-10), 138.98 (C-10a), 
155.59 (Ar-C), 158.12 (Ar-C), 160.80 (C-2). 
19F NMR (DMSO-d6) δ (ppm): -122.89 (Ar-
F). MS m\z (%): 399 (M+, 12.6) with base 
peak at 237. 
 
3,5-Diamino-1-(3,4,5-trimethoxy-phenyl)-
1H-benzo[f]chromene-2-carbonitrile (4h) 
Colorless crystals from ethanol (77 % 
yield), mp 225 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2198 (CN), 3140 (CH); 1H 
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NMR (400 MHz) (DMSO-d6) δ (ppm): 3.61 
(s, 3H, OCH3), 3.66 (s, 6H, OCH3), 5.24 (s, 
1H, H-4), 5.52 (s, 2H, NH2-10), 6.53 (s, 2H, 
Ar-H), 6.94 (s, 2H, NH2-2), 7.03 (s, 1H, Ar-
H), 7.10 (t, J= 9.0 Hz, 1H, Ar-H), 7.23 (t, J= 
9.0 Hz, 1H, Ar-H), 7.56 (d, J= 9.0 Hz, 1H, Ar-
H), 7.73 (d, J= 9.0 Hz, 1H, Ar-H). 13C NMR 
(125 MHz) (DMSO-d6) δ (ppm): 39.08 (C-4), 
56.30 (OCH3), 58.66 (C-3), 60.41 (OCH3), 
104.80 (Ar-CH), 107.52 (C-9), 116.38 (C-4a), 
121.06 (CN), 122.65 (C-5), 123.52 (C-6) 
123.88 (Ar-C), 125.42 (C-7), 126.14 (C-8), 
132.54 (C-4b), 136.70 (C-8a), 138.70 (C-10), 
141.85 (C-10a), 153.47 (Ar-C), 160.41 (C-2). 
MS m\z (%): 403 (M+, 21.5) with base peak 
at 237. 
 
3,5-Diamino-1-thiophen-3-yl-1H-
benzo[f]chromene-2-carbonitrile (4i) 
Colorless crystals from ethanol (71 % 
yield), mp 230 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2196 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 5.38 
(s, 1H, H-4), 5.50 (s, 2H, NH2-10), 6.84 (s, 
1H, Ar-H), 6.95 (s, 2H, NH2-2), 7.01 (s, 1H, 
Ar-H), 7.12 (t, J= 9.0 Hz, 1H, Ar-H), 7.23-
7.25 (m, 2H, Ar-H), 7.35 (br. s, 1H, Ar-H), 
7.56 (d, J= 9.0 Hz, 1H, Ar-H), 7.78 (d, J= 9.0 
Hz, 1H, Ar-H). 13C NMR (125 MHz) 
(DMSO-d6) δ (ppm): 33.94 (C-4), 57.92 (C-
3), 107.26 (C-9), 116.89 (C-4a), 121.05 (CN), 
121.09 (Ar-CH), 122.52 (C-5), 123.25 (C-6) 
123.54 (C-4b), 125.32 (C-7), 126.05 (Ar-
CH), 127.00 (C-8), 127.11 (Ar-CH), 132.43 
(C-8a), 136.66 (C-10), 138.29 (Ar-C), 146.33 
(C-10a), 160.89 (C-2). MS m\z (%): 319 (M+, 
18.6) with base peak at 237. 
Preparation of 2,7-diamino-4-aryl-4H-ben-
zochromene-2-carbonitrile (7a-e) 
A mixture of 5-amino-1-naphthol 
(10 mmol), malononitrile (10 mmol) and aro-
matic aldehyde (10 mmol) were dissolved in 
EtOH (15 ml), then piperidine (0.5 ml) was 
added. The mixture was refluxed for 2-4 
hours until complete precipitation occurred. 
The isolated precipitate was filtered, washed 
with ethanol and recrystallized from ethanol. 
Characterization of the new compounds was 
achieved using NMR, FTIR and mass spec-
trometry. 
 
2,7-Diamino-4-(4-tert-butyl-phenyl)-4H-
benzo[h]chromene-3-carbonitrile (7a) 
Gray crystals from ethanol (75 % yield), 
mp 210 °C; IR (KBr) cm-1: 3320, 3425, 3490 
(NH2), 2190 (CN), 3140 (CH); 1H NMR (400 
MHz) (DMSO-d6) δ (ppm): 1.23 (s, 9H, CH3), 
4.80 (s, 1H, H-4), 5.76 (s, 2H, NH2-8) 6.71 (d, 
J= 9.0 Hz, 1H, Ar-H), 6.95 (d, J= 9.0 Hz, 1H, 
Ar-H), 7.05 (s, 2H, NH2-2), 7.15 (d, J= 9.0 
Hz, 2H, Ar-H), 7.26-7.34 (m, 3H, Ar-H), 7.44 
(d, J= 9.0 Hz, 1H, Ar-H), 7.75 (d, J= 9.0 Hz, 
1H, Ar-H). 13C NMR (125 MHz) (DMSO-d6) 
δ (ppm): 31.09 (CH3), 34.10 (C-CH3), 40.48 
(C-4), 56.18 (C-3), 107.99 (C-7), 108.34 (C-
5), 117.64 (CN), 118.62 (C-4a), 120.77 (C-
10), 122.02 (C-8a), 123.43 (C-9), 124.05 (C-
6), 125.38, 127.10 (Ar-CH), 127.41 (C-4b), 
142.91 (C-8), 144.87 (Ar-C), 149.04 (C-10a), 
160.38 (C-2). MS m\z (%): 369 (M+, 18.6) 
with base peak at 237. 
 
2,7-Diamino-4-(4-methoxy-phenyl)-4H-
benzo[h]chromene-3-carbonitrile (7b) 
Gray crystals from ethanol (75 % yield), 
mp 185 °C; IR (KBr) cm-1: 3320, 3425, 3490 
(NH2), 2190 (CN), 3140 (CH); 1H NMR (400 
MHz) (DMSO-d6) δ (ppm): 3.71 (s, 3H, 
OCH3), 4.79 (s, 1H, H-4), 5.78 (s, 2H, NH2-
8), 6.72 (d, J= 9.0 Hz, 1H, Ar-H), 6.87 (d, J= 
9.0 Hz, 2H, Ar-H), 6.92 (d, J= 9.0 Hz, 1H, Ar-
H), 7.05 (s, 2H, NH2-2), 7.15 (d, J= 9.0 Hz, 
2H, Ar-H), 7.30 (t, J= 9.0 Hz, 1H, Ar-H), 7.45 
(d, J= 9.0 Hz, 1H, Ar-H), 7.74 (d, J= 9.0 Hz, 
1H, Ar-H). 13C NMR (125 MHz) (DMSO-d6) 
δ (ppm): 40.52 (C-4), 55.44 (OCH3), 56.84 
(C-3), 108.43 (C-7), 108.79 (C-5), 114.41 
(Ar-CH), 118.15 (C-10), 118.99 (CN), 121.18 
(C-4a), 122.41(C-9), 123.89 (C-8a), 124.47 
(C-4b), 127.88 (C-6), 129.09 (Ar-CH), 
138.45 (Ar-C), 143.18 (C-8), 145.33 (C-10a), 
158.53 (Ar-C), 160.60 (C-2). MS m\z (%): 
343 (M+, 18.6) with base peak at 237. 
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2,7-Diamino-4-(2,4,6-trifluoro-phenyl)-
4H-benzo[h]chromene-3-carbonitrile (7d) 
Greenish crystals from ethanol (52 % 
yield), mp 235 °C; IR (KBr) cm-1: 3320, 
3425, 3490 (NH2), 2190 (CN), 3140 (CH); 1H 
NMR (400 MHz) (DMSO-d6) δ (ppm): 5.10 
(s, 1H, H-4), 7.16 (d, J= 9.0 Hz, 1H, Ar-H), 
7.29 (s, 2H, NH2-8), 7.38 (d, J= 9.0 Hz, 1H, 
Ar-H), 7.48 (d, J= 9.0 Hz, 2H, Ar-H), 7.67-
7.72 (m, 3H, Ar-H & NH2-2), 7.93 (d, J= 9.0 
Hz, 1H, Ar-H), 8.24 (d, J= 9.0 Hz, 1H, Ar-H). 
13C NMR (125 MHz) (DMSO-d6) δ (ppm): 
40.91 (C-4), 55.92 (C-3), 114.75 (C-7), 
118.02 (Ar-CH), 119.44 (CN), 120.17 (C-6), 
120.59 (C-5), 122.78 (C-4a), 123.76 (C-10), 
126.05 (C-8a), 127.58 (C-9), 128.18 (C-6), 
128.91, 129.88 (Ar-CH), 139.84 (C-4b), 
143.33 (C-8), 148.12 (Ar-C), 150.49 (C-10a), 
160.62 (C-2), 160.88 (Ar-C); 19F NMR 
(DMSO-d6) δ (ppm): -116.11 (Ar-F). MS m\z 
(%): 367 (M+, 12.6) with base peak at 237. 
 
2,7-Diamino-4-thiophen-2-yl-4H-
benzo[h]chromene-3-carbonitrile (7e) 
Gray crystals from ethanol (64 % yield), 
mp 232 °C; IR (KBr) cm-1: 3320, 3425, 3490 
(NH2), 2190 (CN), 3140 (CH), 1H NMR (400 
MHz) (DMSO-d6) δ (ppm): 5.21 (s, 1H, H-4), 
5.80 (s, 2H, NH2-8), 6.74 (d, J= 9.0 Hz, 1H, 
Ar-H), 6.95 (t, J= 9.0 Hz, 1H, Ar-H), 7.07-
7.12 (m, 3H, Ar-H), 7.17 (s, 2H, NH2-2), 7.30 
(t, J= 9.0 Hz, 1H, Ar-H), 7.37 (d, J= 9.0 Hz, 
1H, Ar-H), 7.44 (d, J= 9.0 Hz, 1H, Ar-H), 
7.81 (d, J= 9.0 Hz, 1H, Ar-H). 13C NMR (125 
MHz) (DMSO-d6) δ (ppm): 37.02 (C-4), 
57.17 (C-3), 107.99 (C-7), 108.34 (C-5), 
117.64 (CN), 118.62 (C-4a), 120.77 (C-10), 
122.02 (C-8a), 123.43 (C-9), 124.05 (C-6), 
125.38, 127.10 (Ar-CH), 127.41 (C-4b), 
142.91 (C-8), 144.87 (Ar-C), 149.04 (C-10a), 
160.38 (C-2). MS m\z (%): 319 (M+, 18.6) 
with base peak at 237. 
Preparation of chromene-based azo dyes 
Synthesis of resorcinol azo dyes (12a-k)  
Azo dye compounds were prepared using 
previously reported method (Afifi, 2003).  
 
4-(p-tolyldiazenyl)-benzene-1,3-diol (12a) 
Orange crystals from ethanol (86 % 
yield), mp 185 °C; IR (KBr) cm-1: 3310 (OH), 
1473 (N=N); 1H NMR (400 MHz) (DMSO-
d6) δ (ppm): 2.42 (s, 3H, CH3), 6.38 (s, 1H, 
Ar-H), 6.54 (d, J= 9.0 Hz, 1H, Ar-H), 7.29 (d, 
J= 9.0 Hz, 2H, Ar-H), 7.65-7.69 (m, 3H, Ar-
H), 10.04 (br s, 1H, OH), 13.61 (s, 1H, OH). 
13C NMR (125 MHz) (DMSO-d6) δ (ppm): 
21.30 (CH3), 103.29, 109.08, 121.28, 129.84, 
132.18 (Ar-CH), 134.54, 140.18, 148.00, 
156.05, 162.53 (Ar-C).  
 
4-(4-Methoxy-phenylazo)-benzene-1,3-diol 
(12b) 
Orange crystals from ethanol (84 % 
yield), mp 187 °C; IR (KBr) cm-1: 3325 (OH), 
1500 (N=N); 1H NMR (400 MHz) (DMSO-
d6) δ (ppm): 3.87 (s, 3H, CH3), 6.40 (s, 1H, 
Ar-H), 6.55 (d, J= 9.0 Hz, 1H, Ar-H), 6.99 (d, 
J= 9.0 Hz, 2H, Ar-H), 7.65 (d, J= 9.0 Hz, 1H, 
Ar-H), 7.75(d, J= 9.0 Hz, 2H, Ar-H), 9.87 (s, 
1H, OH), 13.53 (s, 1H, OH). 13C NMR (125 
MHz) (DMSO-d6) δ (ppm): 55.52 (CH3), 
103.34, 108.85, 114.41, 123.04, 132.12 (Ar-
CH), 134.24, 144.37, 155.56, 161.09, 161.99 
(Ar-C). 
 
4-(4-Nitro-phenylazo)-benzene-1,3-diol 
(12c) 
Reddish orange crystals from ethanol 
(89 % yield). mp 192 °C; IR (KBr) cm-1: 3340 
(OH), 1477 (N=N); 1H NMR (400 MHz) 
(DMSO-d6) δ (ppm): 6.38 (S, 1H, Ar-H), 6.52 
(d, J= 9.0 Hz, 1H, Ar-H), 7.68 (d, J= 9.0 Hz, 
2H, Ar-H), 7.92 (d, J= 9.0 Hz, 2H, Ar-H), 
8.07 (d, J= 9.0 Hz, 2H, Ar-H), 10.73 (br s, 1H, 
OH), 12.46 (s, 1H, OH). 13C NMR (125 MHz) 
(DMSO-d6) δ (ppm): 103.02, 109.75, 121.55, 
129.47, 130.49, 132.85 (Ar-CH), 136.98, 
153.18, 157.59, 164.07(Ar-C). 
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1-[4-(2,4-Dihydroxy-phenylazo)-phenyl]-
ethanone (12d) 
Red crystals from ethanol (84 % yield), 
mp 220 °C; IR (KBr) cm-1: 3350 (OH), 
1450(N=N); 1H NMR (400 MHz): 2.64 (s, 
3H, CH3), 6.36 (s, 1H, Ar-H), 6.57 (d, J= 9.0 
Hz, 1H, Ar-H), 7.66 (d, J= 9.0 Hz, 1H, Ar-H), 
7.84 (d, J= 9.0 Hz, 2H, Ar-H), 8.06 (d, J= 9.0 
Hz, 2H, Ar-H), 10.43 (br s, 1H, OH), 13.65 (s, 
1H, OH). 13C NMR (125 MHz) (DMSO-d6) δ 
(ppm): 26.69 (CH3), 103.23, 110.25, 121.10, 
129.43, 132.84 (Ar-CH), 134.92, 136.86, 
152.65, 157.74, 164.28(Ar-C), 196.79 (C=O). 
 
4-(2,4-Dihydroxy-phenylazo)-benzoic acid 
(12e) 
Red crystals from ethanol (84 % yield), 
mp 300 °C; IR (KBr) cm-1: 3320 (Br OH), 
1510 (N=N); 1H NMR (400 MHz): 6.43 (s, 
1H, Ar-H), 6.53 (br.s, 1H, Ar-H), 7.64 (d, J= 
9.0 Hz, 1H, Ar-H), 7.89-8.05 (m, 4H, Ar-H), 
11.00 (br s, 1H, OH), 12.02 (br s, 1H, OH), 
12.39 (br. s, 1H, OH). 13C NMR (125 MHz) 
(DMSO-d6) δ (ppm): 103.14, 104.79, 109.88, 
121.65, 122.54, 129.43, 130.67 (Ar-CH), 
132.09, 153.32, 154.07, 161.35 (Ar-C), 
166.79 (C=O). 
 
4-(4-Hydroxy-phenylazo)-benzene-1,3-diol 
(12i & 12j) 
Reddish orange crystals from ethanol 
(84 % yield), mp 210 °C; IR (KBr) cm-1: 3350 
(OH), 1515 (N=N); 1H NMR (400 MHz): 
6.32 (d, J= 9.0 Hz, 1H, Ar-H), 6.47 (dd, J= 
9.0 Hz, 2H, Ar-H), 7.62 (d, J= 9.0 Hz, 1H, Ar-
H), 7.73 (d, J= 9.0 Hz, 2H, Ar-H), 10.15 (br 
s, 1H, OH), 10.36 (br s, 1H, OH), 12.49 (s, 
1H, OH). 13C NMR (125 MHz) (DMSO-d6) δ 
(ppm): 103.56, 107.00, 109.71, 114.74, 
118.01, 130.67, 131.99 (Ar-CH), 132.63, 
152.17, 156.82, 158.85, 163.47 (Ar-C). 
 
Synthesis of azo dye based chromene 
(13a-k) 
To a mixture of aryl azo dyes 12a-h 
(1 mmol), malononitrile (1 mmol), various 
benzaldehyde in ethanol (10 mL) and piperi-
dine (0.3 mL) was added under rapid stirring. 
The reaction was refluxed for 5 h and the solid 
was filtered and recrystallized from ethanol to 
afford the pure product. 
 
2-Amino-4-(4-fluoro-phenyl)-7-hydroxy-6-
p-tolylazo-4H-chromene-3-carbonitrile 
(13a) 
Brown crystals from ethanol (55 % yield), 
mp 203 °C; UV/Vis (EtOH): λmax= 380 nm; 
IR (KBr) (cm-1): 3410, 3327 (NH2), 3203 
(OH), 2920 (CH3) 2191(CN), 1456 (N=N); 1H 
NMR (400 MHz) (DMSO) δ: 2.41 (s, CH3, 
3H), 4.83(s, IH, H-4), 6.77 (d, J= 9.0 Hz, 1H, 
Ar-H), 7.04 (br. S, 2H, NH2), 7.11 (d, J= 9.0, 
2H, Ar-H), 7.23-7.26 (m, 2H, Ar-H), 7.71-
7.78 (m, 4H, Ar-H), 7.91 (d, J=9.0 Hz, 1H, 
Ar-H), 11.86 (s, 1H, OH). 13C NMR (125 
MHz) (DMSO-d6) δ (ppm): 21.44 (CH3), 
35.80 (C-4), 59.61 (C-3), 108.27 (C-8), 
112.03 (CN), 115.08 (Ar-CH), 115.22 (C-5), 
120.09 (C-4a), 121.86, 129.04 (Ar-CH), 
129.09 (C-6), 129.99, 132.55, 134.11 (Ar-
CH), 140.18 (Ar-C), 141.73, 147.71 (Ar-CH), 
151.63 (C-7), 151.96 (Ar-C), 159.50 (C-8a), 
160.70 (C-2), 162.32 (Ar-C). 19F NMR 
(DMSO-d6) δ (ppm): -116.24 (Ar-F). MS m\z 
(%): 400 (M+, 20.5) with base peak at 237. 
 
2-Amino-4-(4-fluoro-phenyl)-7-hydroxy-6-
(4-methoxy-phenylazo)-4H-chromene-3-
carbonitrile (13b) 
Brown crystals from ethanol (40 % yield), 
mp 272 °C; UV/Vis (EtOH): λmax= 386 nm; 
IR (KBr) (cm-1): 3414, 3336 (NH2), 3223 
(OH), 2185 (CN), 1464 (N=N); 1H NMR (400 
MHz) (DMSO-d6) δ (ppm): 3.84 (s, 3H, CH3), 
4.79 (s, 1H, H-4), 6.79 (d, J= 9.0 Hz, 1H, Ar-
H) 7.03 (br. S, 2H, NH2), 7.07-7.14 (m, 4H, 
Ar-H), 7.21-7.25 (m, 2H, Ar-H), 7.74 (d, J= 
9.0 Hz, 1H, Ar-H), 7.93 (d, J= 9.0 Hz, 2H, Ar-
H), 12.23 (br. s, 1H, OH). 13C NMR (125 
MHz) (DMSO-d6) δ (ppm): 35.85(C-4), 55.60 
(CH3), 57.08 (C-3), 108.03 (C-8), 112.11 
(CN), 114.59 (Ar-CH), 115.01 (C-5), 115.22 
(Ar-CH), 120.08 (C-4a), 124.32 (Ar-CH), 
125.46 (C-6), 129.01, 134.46 (Ar-CH), 
141.23 (Ar-C), 144.80 (Ar-CH), 151.41 (C-
7), 151.83 (C-8a), 159.69 (Ar-C), 161.82 (C-
2), 162.10 (Ar-C). 19F NMR (DMSO-d6) δ 
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(ppm): -116.26 (Ar-F). MS m\z (%): 416 (M+, 
22.5) with base peak at 186. 
 
2-Amino-4-(4-fluoro-phenyl)-7-hydroxy-6-
(4-nitro-phenylazo)-4H-chromene-3-car-
bonitrile (13c) 
Brown crystals from ethanol (41 % yield), 
mp 254 °C; UV/Vis (EtOH): λmax= 390 nm; 
IR (KBr) (cm-1): 3387,3313 (NH2, OH), 2185 
(CN), 1458 (N=N); 1H NMR (400 MHz) 
(DMSO-d6) δ (ppm): 4.79 (s, 1H, H-4), 6.80 
(d, J= 9.0 Hz, 1H, Ar-H) 7.06 (s, 2H, NH2), 
7.13 (t, J= 9.0 Hz, 2H, Ar-H), 7.22-7.26 (m, 
2H, Ar-H), 7.77 (d, J= 9.0 Hz, 1H, Ar-H), 
8.06 (dd, J= 8.6 Hz, 4H, Ar-H), 12.17 (br. s, 
1H, OH). 13C NMR (125 MHz) (DMSO-d6) δ 
(ppm): 35.85 (C-4), 57.17 (C-3), 108.69 (C-
8), 112.39 (CN), 115.03 (Ar-CH), 115.24 (C-
5), 119.95 (C-4a), 122.49, 124.58, 128.99 
(Ar-CH), 129.07 (C-6), 129.35, 135.12, 
137.86 (Ar-CH), 141.14 (Ar-C), 152.80 (C-
7), 153.13, 153.88 (Ar-C), 159.44 (C-8a), 
159.72 (C-2), 162.13 (Ar-C). 19F NMR 
(DMSO-d6) δ (ppm): -116.19 (Ar-F). MS m\z 
(%): 431 (M+, 20.5) with base peak at 237. 
 
6-(4-Acetyl-phenylazo)-2-amino-4-(4-
fluoro-phenyl)-7-hydroxy-4H-chromene-
3-carbonitrile (13d) 
Brown crystals from ethanol (52 % yield), 
mp 265 °C; UV/Vis (EtOH): λmax= 390 nm; 
IR (KBr) (cm-1): 3398, 3313 (NH2), 3196 
(OH), 2187 (CN), 1450 (N=N); 1H NMR (400 
MHz) (DMSO-d6) δ (ppm): 2.62 (s, 3H, CH3), 
4.79 (s, 1H, H-4), 6.81 (d, J= 9.0 Hz, 1H, Ar-
H) 7.06 (s, 2H, NH2), 7.13 (t, J= 9.0 Hz, 2H, 
Ar-H), 7.22-7.26 (m, 2H, Ar-H), 7.78 (d, J= 
9.0 Hz, 1H, Ar-H), 8.07 (dd, J= 6.8 Hz, 4H, 
Ar-H), 12.15 (br. s, 1H, OH). 13C NMR (125 
MHz) (DMSO-d6) δ (ppm): 26.85 (CH3), 
35.85 (C-4), 57.16 (C-3), 108.69 (C-8), 
112.41 (CN), 115.04 (Ar-CH), 115.25 (C-5), 
119.95 (C-4a), 122.51, 124.44, 128.99 (Ar-
CH), 129.07 (C-6), 129.37, 135.15, 137.88, 
141.17 (Ar-CH), 152.81 (C-7), 153.17, 
153.90 (Ar-C), 159.44 (C-8a), 159.72 (C-2), 
162.13 (Ar-C), 197.25 (C=O). 19F NMR 
(DMSO-d6) δ (ppm): -116.20 (Ar-F). MS m\z 
(%): 428 (M+, 30.5  ) with base peak at 109. 
4-[2-Amino-3-cyano-4-(2-fluoro-phenyl)-
7-hydroxy-4H-chromen-6-ylazo]-benzoic 
acid (13e) 
Brown crystals from ethanol (52 % yield), 
mp 243 °C; UV/Vis (DMF): λmax= 388 nm; IR 
(KBr) (cm-1): 3420-3385 (NH2), 2230 (CN), 
1645 (C=O), 1520 (N=N); 1H NMR (400 
MHz) (DMSO) δ: 5.05 (s, IH, H-4), 6.78 (d, 
J= 9.0 Hz, 1H, Ar-H), 7.10 (br. s, 2H, NH2), 
7.13-7.17 (m, 3H, Ar-H), 7.24-7.27 (m, 1H, 
Ar-H), 7.78 (d, J= 9.0 Hz, 1H, Ar-H), 7.95 (d, 
J=9.0 Hz, 2H, Ar-H), 8.03 (d, J=9.0 Hz, 2H, 
Ar-H), 10.92 (br. S, 1H, COOH). 13C NMR 
(125 MHz) (DMSO-d6) δ (ppm): 31.35 (C-4), 
55.95 (C-3), 108.50 (C-8), 111.69 (CN), 
115.85 (Ar-CH), 116.06 (C-5), 120.58 (C-4a), 
122.46, 124.85, 129.16, 130.35, 130.58 (Ar-
CH), 132.16 (C-6), 135.42 (Ar-CH), 152.61 
(C-7), 153.30, 154.32 (Ar-C), 159.16 (C-8a), 
160.25 (C-2), 161.69 (Ar-C), 168.61 
(C=O).19F NMR (DMSO-d6) δ (ppm): -
119.76 (Ar-F). MS m\z (%): 430 (M+, 20.5) 
with base peak at 237. 
 
4-[2-Amino-3-cyano-4-(2-fluoro-phenyl)-
7-hydroxy-4H-chromen-6-ylazo]-benzene-
sulfonic acid (13f) 
Brown crystals from ethanol (59 % yield), 
mp 290 °C; UV/Vis (DMF): λmax = 390 nm; 
IR (KBr) (cm-1): 3450- 3425 (NH2), 
2220(CN), 1495 (N=N); 1H NMR (400 MHz) 
(DMSO) δ: 5.04(s, IH, H-4), 6.80 (d, J= 9.0 
Hz, 1H, Ar-H), 7.08 (br. s, 2H, NH2), 7.11-
7.16 (m, 3H, Ar-H), 7.22-7.27 (m, 1H, Ar-H), 
7.73 (d, J= 9.0 Hz, 3H, Ar-H), 7.78 (d, J= 9.0 
Hz, 1H, Ar-H), 7.92 (d, J=9.0 Hz, 2H, Ar-H), 
11.77 (br. s, 1H, OH). 13C NMR (125 MHz) 
(DMSO-d6) δ (ppm): 31.31 (C-4), 56.01 (C-
3), 107.73 (Ar-CH), 108.65 (C-8), 111.55 
(CN), 115.86 (Ar-CH), 116.08 (C-5), 120.45 
(C-4a), 122.56, 125.01, 127.08, 129.12, 
130.34 (Ar-CH), 131.97 (C-6), 135.25 (Ar-
CH), 150.69 (Ar-C), 151.04 (C-7), 153.04, 
153.65 (Ar-C), 159.15 (C-8a), 160.25 (C-2), 
161.59 (Ar-C). 19F NMR (DMSO-d6) δ 
(ppm): -119.77 (Ar-F). MS m\z (%): 466 (M+, 
20.5) with base peak at 237. 
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4-[2-Amino-4-(4-tert-butyl-phenyl)-3-cy-
ano-7-hydroxy-4H-chromen-6-ylazo]-ben-
zenesulfonic acid (13g) 
Brown crystals from ethanol (67 % yield), 
mp 330 °C; UV/Vis (DMF): λmax = 386 nm; 
IR (KBr) (cm-1): 3430-3400 (NH2), 2225 
(CN), 1510 (N=N); 1H NMR (400 MHz) 
(DMSO) δ: 1.23 (s, 9H, CH3), 4.73 (s, IH, H-
4), 6.81 (d, J= 9.0 Hz, 1H, Ar-H), 7.05 (br. s, 
2H, NH2), 7.11(d, J=9.0 Hz, 2H, Ar-H), 7.32 
(d, J=9.0 Hz, 2H, Ar-H), 7.73-7.79 (m, 3H, 
Ar-H), 7.93 (d, J=9.0 Hz, 2H, Ar-H). 13C 
NMR (125 MHz) (DMSO-d6) δ (ppm): 31.53 
(CH3), 34.53 (C-CH3), 36.37 (C-4), 57.61 (C-
3), 108.74 (C-8), 113.13 (CN & C-5), 120.73 
(C-4a), 122.46 (Ar-CH), 124.95 (C-6), 
125.67, 127.02, 127.15, 135.23, 142.42 (Ar-
CH), 149.30, 150.71 (Ar-C), 150.92 (C-7), 
152.76 (Ar-C), 153.32 (C-8a), 160.08 (C-2). 
MS m\z (%): 504 (M+, 20.5) with base peak 
at 237. 
 
4-[2-Amino-4-(4-butyl-phenyl)-3-cyano-7-
hydroxy-4H-chromen-6-ylazo]-benzene-
sulfonic acid (13h) 
Brown crystals from ethanol (63 % yield), 
mp 275 °C; UV/Vis (DMF): λmax = 385 nm; 
IR (KBr) (cm-1): 3450, 3425 (NH2), 2210 
(CN), 1510 (N=N); 1H NMR (400 MHz) 
(DMSO) δ: 0.88 (t, J=6.0 Hz, 3H, CH3), 1.26-
1.31 (m, 2H, CH2), 1.47-1.55 (m, 2H, CH2), 
2.49 (br. s, 2H, CH2), 4.73 (s, IH, H-4), 6.81 
(d, J= 9.0 Hz, 1H, Ar-H), 7.05 (br. s, 2H, 
NH2), 7.07-7.13 (m, 4H, Ar-H), 7.73-7.80 (m, 
3H, Ar-H), 7.93 (d, J=9.0 Hz, 2H, Ar-H), 
11.93 (br. S, 1H, OH). 13C NMR (125 MHz) 
(DMSO-d6) δ (ppm): 14.14 (CH3), 22.23 
(CH2), 33.52 (CH2), 34.85 (CH2), 36.51 (C-
4), 57.65 (C-3), 108.73 (C-8), 113.12 (CN & 
C-5), 120.67 (C-4a), 122.43 (Ar-CH), 125.10 
(C-6), 127.01, 127.40, 128.74, 135.19, 141.08 
(Ar-CH), 142.66 (Ar-C), 150.86 (C-7), 
152.72 (Ar-C), 153.31 (C-8a), 160.03 (C-2). 
MS m\z (%): 504 (M+, 20.5) with base peak 
at 237. 
 
2-Amino-4-(4-tert-butyl-phenyl)-7-hy-
droxy-6-(4-hydroxy-phenylazo)-4H-
chromene-3-carbonitrile (13i) 
Brown crystals from ethanol (79 % yield), 
mp 255 °C; UV/Vis (DMF): λmax = 387 nm; 
IR (KBr) (cm-1): 3350- 3300 (NH2), 2215 
(CN), 1520 (N=N); 1H NMR (400 MHz) 
(DMSO) δ: 1.23 (s, 9H, CH3), 4.72 (s, IH, H-
4), 6.75 (d, J= 9.0 Hz, 1H, Ar-H), 6.87 (d, J= 
9.0 Hz, 2H, Ar-H), 7.01 (br. s, 2H, NH2), 7.11 
(d, J=9.0 Hz, 2H, Ar-H), 7.31 (d, J=9.0 Hz, 
2H, Ar-H), 7.70 (d, J= 9.0 Hz, 1H, Ar-H), 
7.80 (d, J=9.0 Hz, 2H, Ar-H). 31.52 (CH3), 
34.50 (C-CH3), 36.40 (C-4), 57.63 (C-3), 
107.81 (C-8), 113.03 (CN), 116.58 (Ar-CH & 
C-5), 120.90 (C-4a), 124.96 (Ar-CH), 125.61 
(Ar-CH & C-6), 127.12, 135.03, 142.61 (Ar-
CH), 143.74 (Ar-C), 149.19 (C-7), 151.61 
(Ar-C), 152.63 (C-8a), 160.28 (C-2), 162.13 
(Ar-C). MS m\z (%): 440 (M+, 20.5) with base 
peak at 237. 
 
2-Amino-4-(2-fluoro-phenyl)-7-hydroxy-6-
(4-hydroxy-phenylazo)-4H-chromene-3-
carbonitrile (13j) 
Red crystals from ethanol (62 % yield), 
mp 260 °C; UV/Vis (DMF): λmax= 387 nm; IR 
(KBr) (cm-1): 3330-3310 (NH2), 2215 (CN), 
1520 (N=N); 1H NMR (400 MHz) (DMSO) 
δ: 5.04 (s, IH, H-4), 6.76 (d, J= 9.0 Hz, 1H, 
Ar-H), 6.88 (d, J= 9.0 Hz, 2H, Ar-H), 7.05 
(br. s, 2H, NH2), 7.11-7.17 (m, 3H, Ar-H), 
7.22-7.27 (m, 1H, Ar-H), 7.71 (d, J= 9.0 Hz, 
2H, Ar-H), 7.81 (d, J=9.0 Hz, 2H, Ar-H). 13C 
NMR (125 MHz) (DMSO-d6) δ (ppm): 31.23 
(C-4), 56.00 (C-3), 108.03 (C-8), 111.28 
(CN), 115.79 (Ar-CH), 116.00 (C-5), 116.48 
(Ar-CH), 120.51 (C-4a), 124.96, 125.04, 
126.05 (Ar-CH), 129.06 (Ar-C), 130.29 (Ar-
CH), 132.07 (C-6), 134.79, 144.00 (Ar-CH), 
151.88 (C-7), 152.35 (Ar-C), 159.08 (C-8a), 
160.35 (C-2), 161.61 (Ar-C). 19F NMR 
(DMSO-d6) δ (ppm): -119.70 (Ar-F). MS m\z 
(%): 402 (M+, 20.5) with base peak at 237. 
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2-Amino-4-(2-fluoro-phenyl)-7-hydroxy-6-
(3-hydroxy-phenylazo)-4H-chromene-3-
carbonitrile (13k) 
Reddish brown crystals from ethanol 
(68 % yield), mp 280 °C; UV/Vis (DMF): 
λmax= 388 nm IR (KBr) (cm-1): 3475 (NH2), 
2220 (CN), 1515 (N=N); 1H NMR (400 MHz) 
(DMSO) δ: 5.04(s, IH, H-4), 6.81(d, J= 9.0 
Hz, 1H, Ar-H), 6.93(d, J= 9.0 Hz, 1H, Ar-H), 
7.10 (br. s, 2H, NH2), 7.13-7.17 (m, 3H, Ar-
H), 7.25-7.27 (m, 1H, Ar-H), 7.31-7.35 (m, 
2H, Ar-H), 7.41 (s, 1H, Ar-H), 7.78 (d, J = 9.0 
Hz, 1H, Ar-H), 9.81 (br. S, 1H, OH), 12.41 
(br. S, 1H, OH). 13C NMR (125 MHz) 
(DMSO-d6) δ (ppm): 31.23 (C-4), 55.94 (C-
3), 107.73 (Ar-CH), 108.60 (C-8), 111.42 
(CN), 115.39, 115.80 (Ar-CH), 116.02 (C-5), 
118.78 (Ar-CH), 120.35 (C-4a), 124.97, 
126.97 (Ar-CH), 129.04 (Ar-C), 130.50 (Ar-
CH), 131.85 (C-6), 134.80 (Ar-CH), 152.16 
(C-7), 152.97, 158.63 (Ar-C), 159.14 (C-8a), 
160.18 (C-2), 161.51 (Ar-C). 19F NMR 
(DMSO-d6) δ (ppm): -119.74 (Ar-F). MS m\z 
(%): 402 (M+, 20.5) with base peak at 237. 
 
BIOLOGICAL STUDIES 
Antimicrobial screening 
The microorganism inoculums were uni-
formly spread using sterile cotton swabs on a 
sterile Petri dish malt extract agar (for fungi) 
and nutrient agar (for bacteria). One hundred 
cubic millimeters of each sample was added 
to each well (10 mm-diameter holes were cut 
in the agar gel, 20 mm apart from one an-
other). The systems were incubated for 24–
48 h at 37 °C (for bacteria) and at 28 °C (for 
fungi). After incubation, the microorganism 
growth was observed. Inhibition zones of the 
bacterial and fungal growth were measured in 
millimeters. Tests were performed in tripli-
cate (Cappuccino and Sherman, 1999; 
Vanden Berghe and Vlientinck, 1991).  
 
Cytotoxic screening 
Human colon carcinoma (HCT-116), hu-
man hepatocellular carcinoma (HEPG-2), ad-
enocarcinomic human alveolar basal epithe-
lial cell (A-549), and human breast adenocar-
cinoma (MCF-7) cell lines were obtained 
from the American Type Culture Collection 
(ATCC, Rockville, MD). The cells were 
grown on RPMI-1640 medium supplemented 
with 10 % inactivated fetal calf serum and 50 
µg/ml gentamycin. The cells were maintained 
at 37 °C in a humidified atmosphere with 5 % 
CO2 and were subcultured two to three times 
a week. Potential cytotoxicity of the com-
pounds was evaluated on tumor cells using 
the method of Gangadevi and Muthumary 
(2007) (Klancnik et al., 2010). The cells were 
grown as monolayers in growth RPMI-1640. 
The monolayers of 104 cells adhered at the 
bottom of the wells in a 96-well microtiter 
plate incubated for 24 h at 37 °C in a humidi-
fied incubator with 5 % CO2. The monolayers 
were then washed with sterile phosphate buff-
ered saline (0.01 M pH 7.2) and simultane-
ously the cells were treated with 100 µL from 
different dilutions of tested sample in fresh 
maintenance medium and incubated at 37 °C. 
A control of untreated cells was made in the 
absence of tested sample. Positive controls 
containing doxorubicin were also tested as a 
reference drug for comparison. Six wells were 
used for each concentration of the test sample. 
Every 24 hours an observation under the in-
verted microscope was made. The number of 
the surviving cells was determined by staining 
the cells with crystal violet (Mosmann, 1983; 
Gangadevi and Muthumary, 2007) followed 
by cell lysing using 33 % glacial acetic acid 
and reading the absorbance at 590 nm using 
microplate reader (SunRise, TECAN, Inc, 
USA) after well mixing. The absorbance val-
ues from untreated cells were considered as 
100 % proliferation. The number of viable 
cells was determined using microplate reader 
as previously mentioned before and the per-
centage of viability was calculated as [1-
(ODt/ODc)] x 100 % where ODt is the mean 
optical density of wells treated with the tested 
sample and ODc is the mean optical density 
of untreated cells. The relation between sur-
viving cells and drug concentration was plot-
ted to get the survival curve of each tumor cell 
line after treatment with the specified com-
pound. The 50 % inhibitory concentration 
(IC50), the concentration required to cause 
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toxic effects in 50 % of intact cells, was esti-
mated from graphic plots. 
Caspase activity assay 
To measure caspase-3 and -7 activities, a 
luminescent Caspase-Glo 3/7 assay was per-
formed. HCT116 and MCF-7 cells were 
seeded onto black 96-well plates at a density 
of 3,500 cells/well. After 24 h the compounds 
that were tested (4a, 4b, and 4c) and a refer-
ence (Doxorubicin) drug at IC50 concentration 
was added. After 48 h a Caspase-Glo 3/7 As-
say (Promega) was performed according to 
the manufacturer’s instructions. After adding 
100 μL of Caspase 3/7 Glo Reagent, cells 
were incubated for 2.5 h at room temperature. 
The luminescence was measured using a 
multi-plate reader (Synergy 4, BioTek) with 
an integration time of 1 second per well. The 
values are the means ± SD of three sets of ex-
periments. 
In vitro inhibitory activity screening of  
E. coli DNA gyrase 
Gyrase B and ParE monomers have only 
modest ATPase activity which is enhanced in 
the case of the holo enzymes and stimulated 
further by DNA. The phosphate released fol-
lowing conversion of ATP into ADP can be 
detected by the addition of malachite green 
solution and measured by monitoring the in-
crease in absorbance at 600 nm. Topoisomer-
ases were purchased from Inspiral is Ltd 
(Norwich, United Kingdom). For the Esche-
richia coli DNA gyrase ATPase assay, the fi-
nal assay composition was 10 nM DNA gy-
rase (a complex of two GyrA and two GyrB 
subunits, the A2B2 complex) 3 mM Tris, pH 
7.5, 24 mM KCl, 2 mM MgCl2, 6.5 % (w/v) 
glycerol, 0.01 mg/ml bovine serum albumin 
(BSA), 2 mM DTT (dithiothreitol), 9 mM 
ATP, and 5 % DMSO solution containing the 
compounds). For E. coli topoisomerase IV 
ATPase assay, the final assay composition 
was 10 nM topoisomerase IV (a complex con-
sisting of two ParC and two ParE subunits), 
40 mM HEPES-KOH, pH 7.6, 100 mM Po-
tassium Glutamate, 25 mM Magnesium Ace-
tate, 10 g/ml single-stranded DNA, 0.2 mg/ml 
BSA, 10 mM DTT, 0.5 mM ATP, and 5 % 
DMSO solution containing the compounds. 
The reactions were started by the addition of 
the ATP, and the reaction mixtures were al-
lowed to incubate at 30 °C for 60 mins. Reac-
tions were stopped by adding Malachite green 
solution (0.034 % malachite green, 10 mM 
ammonium molybdate, 1M HCl, 3.4 % Etha-
nol, 0.01 % Tween 20). Color was allowed to 
develop for 5 min, and the absorbance at 
600 nm was measured spectrophotometri-
cally. The half-maximum (50 %) inhibitory 
concentration (IC50) values were determined 
from the absorbance readings using no-com-
pound and no-enzyme controls. The values 
reported are the averages of at least four inde-
pendent experiments. 
Acute toxicity 
In vitro experiments were carried out at 
the University of Prince Edward Island and 
approved by the Animal Care and Biosafety 
Committees, which adheres to the guidelines 
of the Canadian Council on Animal Care 
(protocol #14-041 and 15-028). Mixed neo-
cortical cultures, containing both neurons and 
glia, were prepared from fetal rats at 17-18 
days gestation. Briefly, embryonic tissue was 
extracted from untimed pregnant Sprague-
Dawley rats by caesarean section and trans-
ferred to ice-cold Hanks Balanced Salt Solu-
tion (Gibco). Cortical brain tissue was care-
fully isolated by fine dissection using aseptic 
techniques. Cortices were minced in cold 
HBSS using a sterile razor blade prior to di-
gestion with 0.0125 % trypsin. Dissociated 
cells were plated in poly-L-lysine (1 mg/ml, 
Sigma Aldrich) coated 96 well plates at a 
seeding density of 50000 cells/well in warm 
(37 °C) Dulbecco’s Modified Eagle Medium 
(Gibco) containing 10 % iron-supplemented 
bovine calf serum (Hyclone) and 1 % antibi-
otic/antimycotic (Gibco). Cultures were al-
lowed to adhere overnight in a humidified 
37 °C incubator having 5 % CO2 and atmos-
pheric oxygen. The following day, the media 
was replaced with warmed Neurobasal A Me-
dium (Gibco) containing 0.5 mM L-glutamine 
(Gibco) and supplemented with 1 % B27, N2 
and antibiotic/antimycotic (Gibco). Half-vol-
ume media changes were made every 4 days 
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thereafter with experiments being carried out 
on 14–16 day old cultures. After 14 days in 
culture, the medium was replaced with deox-
ygenated unsupplemented glucose-free Neu-
robasal A containing either 10 or 100 µM of 
the novel compounds T3, T4, T5, T8, T9, 
T11, or T12. Control wells contained glucose-
free medium plus vehicle – either 0.1 % etha-
nol or 0.1 % DMSO. Cultures were trans-
ferred to a humidified 37 °C incubator having 
5 % CO2, 1.1 % O2 and the balance N2 for a 
period of 24 hours. Following OGD, an equal 
volume of normal supplemented Neurobasal 
A containing identical drug concentrations 
was added and cultures were transferred to 
normoxic conditions (5 % CO2 and atmos-
pheric oxygen) for an additional 24 h. Cell vi-
ability was assessed by measuring LDH re-
lease from damaged cells. Control cultures 
were prepared in separate plates having sup-
plemented Neurobasal A and being main-
tained in 5 % CO2 and atmospheric oxygen 
for the duration of the experiment. Toxicity 
was assessed in wells treated with 10 µM of 
each of the test compounds listed above. After 
24 h an equal volume of culture media as 
added to each well to account for handling ef-
fects on experimental outcomes. Toxicity was 
assessed after an additional 24 h in culture by 
measuring LDH release from treated cells. At 
the end of each experiment, cell injury was as-
sessed by measuring lactate dehydrogenase 
(LDH) released from damaged cells into the 
culture medium (Cytoscan LDH Assay, G Bi-
osciences). LDH measurements represent the 
average of 7 replicate treatments/dose. The 
effect of OGD and drug treatments on LDH 
was expressed as a percent of LDH release 
compared to OGD and vehicle groups. Treat-
ments were compared using a one-way 
ANOVA followed by Bonferroni post-hoc 
analysis. Differences were considered signif-
icant if p < 0.05.  
 
Qualitative chelation analysis 
Spectroscopic analysis of chelation prop-
erty of novel compounds were identified us-
ing chemical reaction with ferric chloride. It 
was done by dissolving of 0.5 gm of com-
pound 4c as a representative example in 5 ml 
of methanol and 0.5 ml of diluted HCl. The 
solution was then mixed with equivalent 
amount of ferric chloride reagent with stirring 
for 1 h. The absorbance for reaction mixture 
and single compound was measured using 
UV-Visible Spectrophotometer Evolution 
201 (Thermoscientific). 
 
 Computational analysis 
2D QSAR-based descriptors analysis 
All molecular descriptors supplied by the 
program MOE were computed for QSAR 
analysis. QSAR-Contingency (Molecular 
Operating Environment (MOE), Chemical 
Computing Group, 2012; Hogg et al., 1993), 
a statistical application in MOE, was used for 
the selection of relevant descriptors. PLS 
analysis was performed to determine the rela-
tionship between these 2D molecular de-
scriptors and biological activity of the com-
pounds. The predictive ability of the model 
was determined by classical leave one out 
(LOO) and leave one pair out cross validation 
procedures. 
Docking studies 
Docking was carried out to the active 
compounds 4a-c, and 7c with the selective 
pharmacologically important drug targets that 
overexpressed in breast and colon cancers us-
ing docking module implemented in MOE 
software (Molecular Operating Environment 
(MOE), Chemical Computing Group, 2012). 
The drug targets namely epidermal growth 
factor receptor (EGFR) (PDB id: 4HJO), and 
Caspase 3 (PDB id: 2XYP) were retrieved 
from the protein databank (Berman et al., 
2000). Initially all the structures were proto-
nated with addition of polar hydrogens fol-
lowed by energy minimization with 
MMFF94x force field in order to get stabi-
lized conformer of the protein. As per the lit-
erature the inhibitor binding sites were identi-
fied and highlighted with site finder module 
implemented in MOE software and docking 
was carried out with default parameters. 
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RESULTS AND DISCUSSION 
Chemistry 
Synthesis of chromene compounds 
The new compounds have been synthe-
sized using Knoevenagel condensation fol-
lowed by Michael addition adducts (Widelski 
et al., 2009). Two new families of chromene 
compounds were synthesized via multi-com-
ponent reactions (MCRs) in order to examine 
their biological structure activity relationship 
(Figure 2). The first family has been obtained 
via reaction of malononitrile 1 and various 
substituents of aromatic aldehydes 2a-i with 
3-amino-2-naphthol 3 in the presence of pi-
peridine, route A. The solutions were refluxed 
for 2 h and afforded 3,5-diamino-4-aryl-1H-
benzo chromene-2-carbonitrile compounds 
4a-i in 60-77 % yield. The second series of 
chromene derivatives has been prepared using 
the same methodology. Route B illustrates the 
reaction of malononitrile 1 and various alde-
hydes 5a-e with 5-amino-1-naphthol 6 to pro-
duce 2,7-Diamino-4-aryl-4H-benzo[h]chro-
mene-3-carbonitrile 7a-e. 
The structures of the obtained compounds 
4a-i and 7a-e were characterized using FT-IR 
and NMR spectroscopic techniques. For in-
stance, the FT-IR spectroscopy showed a 
characteristic absorption band between 2185 
and 2210 cm-1 for the CN group, while the 
NH2 stretches were in the range of 3320-
3490 cm-1. The 1H NMR spectra of chromene 
compounds 4a-i in DMSO-d6 showed signals 
at 5.09-5.67 ppm for 4-H pyran, while the sin-
glets at 5.43-5.66 ppm are corresponding to 
NH2-10. The NH2-2 has a signal overlapped 
with the aromatic protons in the range of 6.84-
7.78 ppm for all chromene derivatives except 
for compounds 4a and 4g, which had the pro-
tons of NH2-2 as a singlet at δ 6.85 and 
7.05 ppm, respectively. The 13C NMR spectra 
showed a signal at δ 32.96-39.08 ppm corre-
sponding to C-4, while C-3 appeared in the 
range of 56.06-58.66 ppm. The C-2 resonance 
showed signal at 159.71-160.89 ppm and the 
CN resonance was in the range of 120.17-
122.61 ppm. It is also important to mention 
that chromene molecule 7c has been reported 
previously in literature (Yadav et al., 2007), 
while their counterparts 7a, b, d and e have 
not been reported yet.  
 
4a,  Ar = 4-FC6H4                4b,  Ar = 4-ClC6H4                       4c,  Ar = 4-CH3C6H4     
4d,  Ar = 4-OCH3C6H4        4e,  Ar = 2,4-Cl2C6H3                  4f,  Ar = 2,4-F2C6H3   
4g, Ar = 2F, 3CF3C6H3          4h, Ar = 3,4,5-(OCH3)3C6H2       4i,  Ar = 3-Thiophene
OH
NH2
CN
CN
O
H
Ar
Ethanol
O
Ar
CN
NH2
NH2
Piperidine
OH
NH2
O
NH2
CN
Ar
NH2
3 4a-i
2a-i 
or
5a-i
1
6 7a-e
7a,  Ar = 4-C(CH3)3C6H4          7b,  Ar = 4-CH3OC6H4                7c,  Ar = 4-FC6H4    
                            7d,  Ar = 2,4,6-F3C6H2          7e,  Ar = 2-Thiophene
A
B
 
Figure 2: Synthesis of two series of chromene derivatives
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Synthesis of chromene-based azo dyes  
Two different series of chromene com-
pounds have also been prepared using MCR 
in order to use them as precursors for building 
azo dye molecules. Compounds 8a-d and 9a-
d were prepared according to a previous re-
port (Figure 3) (Zheng et al., 2010). Upon the 
synthesis of these two series, they been em-
ployed as amines or as couplers for further re-
action to prepare their azo chromophore coun-
terparts. However, this methodology was not 
successful since the analysis of the obtaining 
materials showed disappearance of the cyano 
group which suggested two possibilities; ei-
ther the formation of the carboxylic acid via 
hydrolysis reaction of the cyano group or the 
pyran ring had been opened during the reac-
tion. To overcome this problem, another at-
tempt had been achieved to prepare the 
chromene azo dye via different approach. The 
new synthetic approach allowed for success-
ful isolation of novel series of azo chromo-
phores via two steps’ methodology. The first 
step included the synthesis of arylazo dyes 
12a-k through reactions of diazonium salts of 
aromatic amines with resorcinol (Afifi, 2003). 
These compounds were then employed for 
further reactions with malononitrile and de-
rivatives of benzaldehyde to obtain the first 
example of azo dyes containing chromene 
moieties 13a-k (Figure 4).  
 
 
Figure 3: 2,7-amino-4-aryl-3-cyano-4H-chrom-
ene (8a-d) and 2-amino-4-aryl-7-hydroxy-3-cy-
ano-4H-chromene (9a-d)series  
 
 
Compounds 13a-k represent a novel class 
of azo dyes. The structures of these new dyes 
were confirmed using the spectroscopic ana-
lytical techniques. In the IR spectra, the ab-
sorptions at 2185-2191 cm-1 were assigned to 
the CN functionality, while the absorptions at 
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13b,  R1 = OCH3,   R2 = H,   Ar = 4-FC6H4
13c,  R1 = NO2,      R2 = H,   Ar = 4-FC6H4
13d,  R1 = COCH3, R2 = H,   Ar = 4-FC6H4
13e,  R1 = COOH,   R2 = H,   Ar = 2-FC6H4
13F,  R1 = SO3H,    R2 = H,   Ar = 2-FC6H4
13g,  R1 = SO3H,    R2 = H,   Ar = 4-C(CH3)3C6H4
13h,  R1 = SO3H,    R2 = H,   Ar = 4-CH3(CH2)3C6H4
13i,   R1 = OH,        R2 = H,   Ar = 4-C(CH3)3C6H4
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Figure 4: Synthesis of azo chromene dyes 13a-k 
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1450-1464 cm-1 were assigned to (N=N) moi-
ety. The 1H NMR spectra showed the pres-
ence of signals for H-4, appearing as a singlet 
in the range of δ 4.72-5.05 ppm, while the 
NH2-2 protons appeared in the range of 7.01-
7.10 ppm. The rest of the aromatic protons of 
the chromene moieties and the arene rings ap-
peared downfield in the range of 7.07-
8.07 ppm. The 13C NMR spectra showed the 
resonance of C-4 at 31.23-36.51 ppm, while 
the CN resonance at 111.28-113.13 ppm and 
C-2 resonance at 159.72-161.82 ppm. And fi-
nally, the 19F NMR spectra showed the pres-
ence of the florin signals between -116.19 and  
-119.77 ppm.  
UV-vis study 
A UV-vis study of azo dyes 12a-k and 
their azo chromene counterparts’ 13a-k was 
performed in DMF in order to explore their 
λmax values. The obtained data showed that 
the formation of the chromene azo derivatives 
did not alter the λmax values of their azo pre-
cursors due to the non-conjugated system of 
the chromene moieties. All azo compounds 
and their azo chromene analogues displayed 
λmax in the range of 390-404 nm.  
 
Prediction of activity spectra for substances 
(PASS)  
The Prediction of Activity Spectra for 
Substances (PASS) has been utilized in order 
to predict the spectrum of activity (Stepanchi-
kova et al., 2003). In this study, we explored 
the biological potential of selected com-
pounds to prioritize them for further in vitro 
studies. The PASS is an in silico tool used for 
predicting biological activity spectra for nat-
ural and synthetic substances, which is based 
on the structure-activity relationships know-
ledgebase for more than 260,000 compounds 
with known biological activities including 
drugs, drug candidates, pharmaceutical leads 
and toxic compounds (Patil et al., 2015). The 
PASS predicts the tentative biological poten-
tial of the compound based on its structure 
and reveals the predicted activities as the 
probability of activity (Pa) and inactivity (Pi). 
The higher the Pa value, the lower the pre-
dicted probability of obtaining false positives 
in biological testing. The PASS analysis re-
vealed that target compounds have high activ-
ity scores as apoptotic agonists with Pa values 
in the 0.851-0.721 range. This prediction 
agrees with previous published work (Elin-
son et al., 2010; Sondhi et al., 2010; Tha-
reja et al., 2010; Trinchieri, 2015). The ob-
tained in silico findings were further validated 
in vitro by different biological analyses in-
cluding the reported antimicrobial activity 
and cytotoxic screening as described below.  
 
Biological screening 
Antimicrobial screening 
All the newly synthesized compounds de-
scribed in this report were screened for both 
antibacterial and antifungal activity via the re-
ported agar diffusion well method (Vanden 
Berghe and Vlietinck, 1991). The inhibition 
zones and minimum inhibitory concentrations 
(MIC) were determined by the serial dilution 
method (Cappuccino and Sherman, 1999). 
The antimicrobial activity of the synthesized 
compounds was tested against a broad panel 
of microorganisms including two Gram-posi-
tive bacteria: Streptococcus pneumoniae 
(RCMB 010010) and Bacillus subtilis 
(RCMB 010067), two Gram-negative bacte-
ria: Pseudomonas aeruginosa (RCMB 
010043) and Escherichia coli (RCMB 
010052), and four fungi: Aspergillus fumiga-
tus (RCMB 02568), Syncephalastrum race-
mosum (RCMB 05922), Geotricum candidum 
(RCMB 05097), and Candida albicans 
(RCMB 05036). Ampicillin, ciprofloxacin, 
gentamicin and amphotericin B were used as 
positive control drugs (Atta-ur-Rahman and 
Thomsen, 2001; Smania et al., 1999). The ob-
served inhibition zone (IZ) and minimum in-
hibitory concentrations (MIC) of the tested 
compounds and the reference drugs are given 
in Tables 1 and 2 and presented in Figures 5 
and 6. It appeared that most of the tested com-
pounds showed appreciable bacterial and fun-
gal inhibition compared to reference drugs. In 
general, these compounds displayed mostly 
inhibitory activity against Gm+ve bacteria re-
sulting in an IZ range from 11 to 33 mm. 
While in the case of Gm-ve bacteria, they had 
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weak activity. In addition, certain strains of 
fungi were sensitive to tested compounds with 
an IZ range from 12-25 except Candida albi-
cans. Among the synthesized compounds, 4b 
and 4d derivatives were found to be more ef-
fective against Gm+ve and fungi with an IZ 
range from 18 to 30 mm and MIC from 0.007 
to 0.49 µg/ml (more potent than positive con-
trols). While compounds 7b and 7d were also 
found to be more active against Gm+ve, Gm-
ve bacteria, and fungi with an IZ ranging from 
18-23 mm. In the case of antibacterial activity 
against Gm+ve bacteria, most of the com-
pounds were found to be comparable to the 
positive controls, having an MIC ranging 
from 3.9 to 0.49 µg/ml.  
 
Table 1: Well diffusion assay for antimicrobial activity of synthetic compounds (Inhibition Zone (IZ) di-
ameter in mm) (5 mg/mL in DMSO) 
Compound Bacteria Fungi 
Gm+ve Gm-ve 
S.P B.S P.A E.C A.F S.R G.C C.A 
1 15.9 17.8 NA 15.5 16.6 14.3 19.2 NA 
4a 16.9 18.2 NA 11.9 12.3 12.6 NA 9.4 
4b 22.6 33.7 13.1 18.3 24.3 17.6 26.9 NA 
4c 18.2 19.4 NA 15.3 20.2 16.9 18.6 NA 
4d 19.5 29.8 12.3 17.6 22.3 16.5 25.8 NA 
5 16.3 18.9 NA 17.2 18.3 14.5 19.5 NA 
7a 16.1 16.9 NA 13.8 15.4 14.1 15.8 NA 
7b 22.4 23.2 NA 22.1 21.6 20.3 22.6 NA 
7c 17.8 21.3 NA 18.6 18.2 16.2 20.1 NA 
7d 21.6 22.3 NA 20.8 20.3 18.1 22.4 NA 
7e 16.3 18.2 NA 15.2 16.4 14.2 16.9 NA 
12c 17.2 18.6 NA 13.5 16.4 14.2 17.9 NA 
12k 20.2 22.2 15.4 18.2 18.2 18.9 20.5 NA 
13a 19.6 23.7 NA 14.4 20.4 17.3 21.4 NA 
13b 17.5 19.7 NA 17.8 16.3 15.2 17.3 NA 
13c 14.6 14.3 NA 9.4 13.6 10.4 NA NA 
13d 12.9 13.2 NA 10.8 13.4 11.4 NA 8.0 
13e 23.6 25.2 19.3 19.3 21.3 19.3 21.8 NA 
13f 10.6 13.4 NA 12.1 10.3 11.6 13.4 NA 
13g 15.2 16.1 NA 13.6 14.3 15.2 17.1 NA 
13h 15.3 16.3 NA 13.9 12.1 13.6 15.8 NA 
13i 21.3 22.4 16.2 17.2 17.3 19.2 20.3 NA 
13j 21.0 21.9 16.3 19.8 20.6 18.7 21.2 NA 
13k 22.6 24.3 17.1 18.6 19.4 17.1 21.3 NA 
Ampicillin 23.8 32.4 - - - - - - 
Gentamicin - - 17.3 19.9 - - - - 
Amphotericin B - - - - 23.7 19.7 28.7 25.4 
Ciprofloxacin - - 22.3 25.3 - - - - 
S.P: Streptococcus pneumoniae; B.S: Bacillus subtilis; P.A: Pseudomonas aeruginosa; E.C: Escherichia coli; A.F: Aspergillus 
fumigatus; S.R: Syncephalastrum racemosum; G.C: Geotricum candidum; C.A: Candida albicans 
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Table 2: Antimicrobial activity of synthetic compounds (Minimum inhibitory concentration, MIC, µg/mL) 
Compound Bacteria Fungi 
Gm+ve Gm-ve  
S.P B.S P.A E.C A.F S.R G.C C.A 
1 15.62 31.25 NA 7.8 15.63 7.81 62.5 NA 
4a 15.63 3.9 NA 7.81 15.63 7.81 NA 125 
4b 0.49 0.007 125 15.63 0.24 31.25 0.03 NA 
4c 7.81 7.81 NA 62.5 3.9 31.25 7.81 NA 
4d 7.81 0.007 125 15.63 0.98 62.5 0.06 NA 
12c 31.25 7.81 NA 125 62.5 125 15.63 NA 
12k 1.95 0.49 62.5 7.81 7.81 3.9 0.98 NA 
13b 31.25 3.9 NA 15.63 62.5 62.5 31.2 NA 
13e 0.12 0.06 3.9 3.9 0.98 3.9 0.49 NA 
13i 0.24 0.12 15.63 3.9 3.9 15.63 0.98 NA 
13j 0.98 0.49 31.25 3.9 0.98 3.9 0.98 NA 
13k 0.98 0.49 31.25 15.63 15.63 3.9 1.95 NA 
Ampicillin 0.24 0.007 - - - - - - 
Gentamicin - - 31.25 3.9 - - - - 
Amphotericin B - - - - 0.24 3.9 0.015 0.12 
Ciprofloxacin - - 0.99 0.49 - - - - 
S.P: Streptococcus pneumoniae; B.S: Bacillus subtilis; P.A: Pseudomonas aeruginosa; E.C: Escherichia coli; A.F: Aspergillus 
fumigatus; S.R: Syncephalastrum racemosum; G.C: Geotricum candidum; C.A: Candida albicans 
 
Figure 5: Heat map of inhibition zone data for the tested compounds against bacterial and fungal strains. 
The values are color-coded and color bars mark the matrix positions of compounds in a particular bac-
teria type. 
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Figure 6: Heat map of MIC data for the tested active compounds against bacterial and fungal strains. 
The values are color-coded and color bars mark the matrix positions of compounds in a particular bac-
teria type. 
 
 
 
The chromene azo derivatives showed 
moderate inhibitory activity against all tested 
microorganisms especially compound 13e, 
13j, and 13j with MIC values of 0.007, 0.12, 
0.49, and 3.9 µg/ml. Generally, the investiga-
tion of antimicrobial activity of the novel de-
rivatives showed, in part, that some of them 
were more potent compared to the positive 
controls used against Gm+ve bacteria and cer-
tain strains of fungi. 
Cytotoxic screening 
The in vitro cytotoxic activity was per-
formed by MTT assay (Mosmann, 1983; 
Alley et al., 1988) against three human carci-
noma cell lines: Human colon carcinoma 
(HCT-116), human breast adenocarcinoma 
(MCF-7), and human hepatocellular carci-
noma (HEPG-2). Doxorubicin was used as a 
positive control with reported high cytotoxic 
activity. The inhibitory effects of tested com-
pounds on the growth of the three cell lines 
are shown in Tables 3 and 4 and Figure 7. All 
compounds showed potent or comparable cy-
totoxicity to the positive control. From the ob-
served data, it was noted that 3-amino-2-
naphthol starting material showed weak anti-
proliferative activity by 60 to 230 µg/mL. The 
activity is dramatically changed by the for-
mation of benzochromene derivatives 4a-g 
with IC50 ranging from 0.3 to 50 µg/mL. 
Three derivatives 4a-c exhibited equally po-
tent activity against three cell lines. Increas-
ing the size of the substituents on the aromatic 
ring led to a loss of activity as in 4h-i. While 
in the case of the starting material 5-amino-1-
naphthol, the activity was moderate with an 
IC50 ranging from 9 to 15 µg/mL. Hence, the 
benzochromene derivatives 7a-e showed 
moderate inhibitory activity towards all cell 
lines ranging from 11.9 to 61.9 µg/mL. One 
derivative displayed potent activity compared 
to the reference drug with an IC50 from 0.7 to 
2 µg/mL against all target cell lines. In the 
case of azo chromene derivatives 13b-k, they 
showed weak to moderate activity compared 
to the reference drugs with an IC50 ranging 
from 10.4 to 100 µg/mL. Of this group, only 
compound 13b displayed potent (IC50 form 
2.41 to 5.4 µg/mL) activity. Thus, most of 
synthesized compounds showed promising 
antiproliferative activity compared to previ-
ously reported work (Yadav et al., 2007; 
Zheng et al., 2010; El-Agrody et al., 2000; 
Sabry et al., 2011), but would need to be im-
proved for further optimization. 
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Table 3: Cytotoxicity of target Benzo Chromene compounds against three different cancer cell lines 
Compound Ar IC50(μg/mL) 
HCT-116 MCF-7 HepG-2 
1 - 218 230 60.5 
4a 4-FC6H4 1.0 1.0 0.3 
4b 4-ClC6H4 1.1 1.0 1.0 
4c 4-CH3C6H4 1.1 0.8 0.3 
4d 4-OCH3C6H4 4.79 4.68 2.64 
4e 2,3-diCl2C6H3 2.0 1.5 1.0 
4f 2,4-diF2C6H3 9.25 6.38 5.22 
4g 2F-3CF3C6H3 30 53.5 32.4 
4h 2,4,6-(OCH3)3C6H2 500 500 500 
4i 3-Thiophene 500 386 188 
5 - 11.5 8.88 15.2 
7a 4-C(CH3)3C6H4 14.3 17.5 11.9 
7b 4-OCH3C6H4 44.1 25.9 28.2 
7c 4-FC6H4 2.0 1.4 0.7 
7d 2,4,6-F3C6H2 61.3 54 52.3 
7e 2-Thiophene 39.9 61.9 33.2 
Doxorubicin - 0.88 1.02 1.19 
Vinblastine - 2.6 6.1 4.6 
Colchicine - 42.8 17.7 10.6 
Imatinib - - 24.6 18.6 
5-Flurouracil - 4.3 3.9 - 
Cytotoxic effects of compounds on colon, breast, and liver cell lines following exposure to different concentrations of compounds, 
and cell viability was assessed using the MTT method. Data are presented as IC50 (µg/ml) values which are means ± SD. 
 
 
Caspase activity assay 
The initial reported assay of 4-aryl-4H-
chromene series were identified as apoptosis 
inducers via caspase activation (Elinson et al., 
2010; Sondhi et al., 2010; Thareja et al., 2010; 
Trinchieri, 2015). Furthermore, it was im-
portant to investigate the antiproliferative ef-
fect of the novel synthesized compounds 4a, 
4b, and 4c using caspase-3 and -7 activities 
compared to doxorubicin and vehicle control 
drug in the corresponding cancer cell lines 
MCF-7 and HCT-116. The resulting data are 
presented in Figure 8. The results indicated 
that all tested compounds significantly in-
creased the concentration of caspases com-
pared to doxorubicin and vehicle control. In 
particular, compound 4b and 4c showed sig-
nificant elevation in the caspase activity com-
pared to control and doxorubicin drug by 2-3 
folds. These results suggested that the anti-
proliferative effect of these derivatives is me-
diated through induction of apoptosis. 
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Table 4: Cytotoxicity of target azo dyes and azo based chromene compounds against three different 
cancer cell lines 
Compound  
R1 
 
R2 
 
Ar 
IC50(μg/mL) 
HCT-116 MCF-7 HepG-2 
12c NO2 H - 30.2 24 21.2 
12k H OH - 100 71.9 22.2 
13b OCH3 H p-F-C6H4- 2.41 3.78 5.4 
13c NO2 H p-F-C6H4- 12.2 10.8 10.4 
13d COCH3 H p-F-C6H4- 75 80 85 
13e COOH H o-F-C6H4- 46.7 27.9 20.5 
13f SO3H H o-F-C6H4- 100 79.8 68.4 
13g SO3H H p-C(CH3)3-C6H4- 100 92.6 81.3 
13h SO3H H p-CH3(CH2)3-C6H4- 88.6 44.6 40.4 
13i OH H p-C(CH3)3-C6H4- 75.7 47 31.6 
13j OH H o-F-C6H4- 49.1 44 47.2 
13k H OH o-F-C6H4- 71.4 44.1 41.8 
Doxurubicin - - - 0.88 1.02 1.19 
Vinblastine - - - 2.6 6.1 4.6 
Colchicine  - - - 42.8 17.7 10.6 
Imatinib - - - - 24.6 18.6 
5-Flurouracil - - - 4.3 3.9 - 
Cytotoxic effects of compounds on colon, breast, and liver cell lines following exposure to different concentrations of compounds, 
and cell viability was assessed using the MTT method. Data are presented as IC50 (µg/ml) values which are means ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: In vitro cytotoxic activity. The IC50 val-
ues of target compounds compared to reference 
drug are color-coded according to the following 
scheme: green 0.5–10, black 11–14, and red 15–
24. Color bars mark the matrix positions of com-
pounds in a particular cell line.
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Figure 8: In vitro analysis of caspases activity for representative target compounds 
 
 
In vitro inhibitory activity screening of  
E. coli DNA gyrase 
Based upon the antimicrobial screening 
data, target compounds 4a, 7c, and 13b were 
evaluated against DNA gyrase from Esche-
richia coli in the DNA supercoiling assay for 
studying their mechanism. The results are 
presented in Table 5 as residual activities (RA 
is the percentage activity of the enzyme in the 
presence of 10 μM and 100 μM of com-
pound). Unfortunately, all tested compounds 
displayed weak activity as DNA gyrase inhib-
itor by 114 % to 137 % residual activities. 
This means that the chromene and azo 
chromene compounds did not affect the anti-
microbial activity through this enzyme target. 
 
 
 
Table 5: DNA Gyrase data for some selected chromene and azo based chromene compounds 
 
 
DNA Gyrase Residual activity [%] 
RA (100 µM) = 128 % 
RA (10 µM) = 125 % 
RA (100 µM) = 127 % 
RA (10 µM) = 137 % 
RA (100 µM) = 114 % 
RA (10 µM) = 117 % 
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Acute toxicity 
Lactate dehydrogenase (LDH) release in 
the medium is an enzymatic indicator that il-
lustrates the loss of membrane integrity, 
apoptosis, or necrosis of a cell. Using a pri-
mary mixed neuronal in vitro culture, the cy-
totoxic effect of the chromene-based com-
pounds (4a, 4c, 7c, 12c, 12k, 13g, and 13h) 
was assessed by lactate dehydrogenase 
(LDH) release from cells pretreated with dif-
ferent concentrations after 24 and 48 h of in-
cubation (Figure 9A-C). It was shown that af-
ter 24 hrs of incubation and using 10 µM con-
centration of drugs, compound 7c and 4a ex-
hibited more LDH release than vehicle by 2-
3 folds, while compound 4c reduced the LDH 
release (Figure 9A). By increasing the con-
centration to 100 µM for 24 hrs, only com-
pound 7c displayed more LDH release com-
pared to the vehicle, while compound 4c was 
ineffective at this concentration (Figure 9B). 
Increasing the incubation time of the com-
pounds to 48 hrs completely abolished the ef-
fect of these compounds (Figure 9C). These 
results confirmed that compounds 7c and 4a 
have a cytotoxic effect of on central nervous 
system tissue. 
 
 
 
Figure 9: Bar chart summarizing the effect of compounds on acute neuronal toxicity. These graphs 
show the acute toxicity of target compounds against neuronal cells. A) The reported toxicity of target 
drugs within 24 h by concentration of 10 µM, B) The reported toxicity of target drugs within 24 h by 
concentration of 100 µM. 
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Figure 9 (cont.): C) The reported toxicity of compounds within 48 h (10 µM). The data represent mean 
with standard error values. 
 
 
 
Qualitative complex metric analysis 
The tendency of the target drugs to work 
through a chelation mechanism with metals 
like iron and calcium, which would be similar 
to the behavior of doxorubicin as reference 
drug, was performed experimentally. The ex-
periment was done by reaction of ferric chlo-
ride as metal source and compound 4c as a 
representative of one of our target com-
pounds. The data are presented in Figure 10, 
showing an absorption peak at λmax equal 361 
nm which is shifted bathochromically due to 
the complexation. The absorption spectrum 
was observed to change from 281 and 342 nm 
for the drug alone, to 361 nm for the drug 
complex. This behavior occurs due to the pos-
sibility of monocomplexation, dicomplexa-
tion or tricomplexation reactions and indi-
cates that these chemical compounds have the 
ability to chelate with metals as part of their 
biological cytotoxic mechanism.  
 
Computational studies and SAR analysis 
2D-QSAR analysis 
In this study, the best multi-linear regres-
sion analysis was utilized a stepwise search 
tool for finding out n-parameter regression 
models (n is the number of descriptors) for re-
lating of structures to activity based upon dif-
ferent parameters coefficients values like 
(correlation coefficients, R2), F value, and 
standard deviation. Three 2D QSAR equa-
tions were built using a set of 28 synthesized 
compounds with regard to each showing anti-
cancer bioactivity in terms of molecular de-
scriptors. These descriptor panels include: to-
tal polar surface area (TPSA), van der Waals 
volume (vdw_vol), partition coefficient 
(logP(o/w), number of hydrogen bonding ac-
ceptor (a_acc), total hydrophobicity surface 
(Q_VSA_HYD), molar refractivity (SMR), 
and van der Waals surface area (vdw_area). 
The QSAR models were generated from up to 
6 descriptors describing the biological activ-
ity of anticancer agents and agree with the 
rule of thumb; 5:1 ratio of compounds to de-
scriptors. The statistical characteristics of all 
models are grouped in Table 6. It is quite clear 
that the models are significant based on statis-
tical parameters. Table 7 reports the distribu-
tion values of descriptors space, while Table 
8 and Figure 11 account for the least correla-
tion analysis among them. The frequency of 
compound set distribution based upon 
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Q_VSA_HYD descriptor is sketched in Fig-
ure 12, showing the differential properties 
among novel derivatives. Figure 13 shows the 
QSAR plots of correlations representing the 
observed versus predicted IC50 for all antipro-
liferative screening. The observed and pre-
dicted data of the training set of compounds 
(1, 4a-I, 5, 7a-e, 12c-k, and 13b-k), with ex-
ception of 4e, 4i, 7c, 13b, and 13f as testing 
sets, are presented in Table 7.  
 
 
 
 
Figure 10: UV-vis study for metal chelation with target compound 4c 
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Table 6: QSAR models with all details including equations, descriptors space, and correlation parame-
ters 
Parameters HCT-116 model MCF-7 model HepG-2 model 
Observations 28 28 28 
DF 24 24 24 
R² 0.90 0.87 0.91 
Std. deviation 54.4 51.1 57.4 
RMSE 50.3 47.3 53.2 
HCT-116  Activity(IC50)=132.83-4.16*Q_VSA_HYD+15.92*a_acc -
0.71*TPSA+2.19*vdw_vol+67.92*logP(o/w) 
MCF-7  Activity(IC50)=137.66-3.65*Q_VSA_HYD+15.56*a_acc-
0.63*TPSA+2.09*vdw_vol+34.04*logP(o/w) 
HepG-2 Activity(IC50)=20.85-2.12*Q_VSA_HYD-0.18*TPSA+0.67*vdw_vol -
60.89*logP(o/w)+33.31*SMR+0.96*vdw_area 
Descriptors space Q_VSA_HYD 
TPSA 
vdw_vol 
logP(o/w) 
a_acc 
Q_VSA_HYD 
TPSA 
vdw_vol 
logP(o/w) 
a_acc 
Q_VSA_HYD 
TPSA 
vdw_vol 
logP(o/w) 
SMR 
vdw_area 
 
 
Table 7: Molecular descriptor values of the QSAR models 
ID Q_VSA_HYD a_acc TPSA vdw_vol logP(o/w) SMR vdw_area 
4a 301.35 1 85.06 437.93 3.47 9.41 301.35 
4b 314.52 1 85.06 450.74 3.91 9.91 314.52 
4c 314.17 1 85.06 459.21 3.62 9.88 314.17 
4e 332.11 1 85.06 466.7 4.5 10.4 332.11 
4d 329.18 2 94.29 469.88 3.28 10.1 329.18 
4f 305.76 1 85.06 441.07 3.66 9.4 305.76 
4g 331.81 1 85.06 471.78 4.44 9.92 331.81 
4h 252.83 4 112.75 540.06 3.26 11.4 393.65 
4i 272.29 1 85.06 529.19 4.93 11.7 358.11 
7a 301.35 1 85.06 437.93 3.43 9.41 301.35 
7b 329.18 2 94.29 469.88 3.24 10.1 329.18 
7c 377.26 1 85.06 532.5 4.78 11.3 377.26 
7d 310.17 1 85.06 444.21 3.81 9.4 310.17 
7e 358.11 1 85.06 529.19 4.77 11.7 358.11 
1 160.68 1 46.25 224.08 2.22 5 160.68 
5 160.68 1 46.25 224.08 2.14 5 160.68 
12c 207.68 4 111 308.78 3.27 6.7 245.64 
12k 227.53 5 85.41 293.4 3.06 6.21 227.53 
13a 368.21 5 124.22 507.25 4.39 10.6 368.21 
13b 390.41 5 113.22 533.82 4.61 11.1 390.41 
13c 348.36 4 149.81 522.63 4.59 11.1 386.32 
13d 375.41 5 121.06 548.77 4.51 11.4 397.44 
13e 361.96 6 141.29 532.86 4.33 11.1 390.23 
13f 366.38 7 158.36 545.69 3.55 11.4 409.9 
13g 442.29 7 158.36 640.26 4.9 13.3 485.82 
13h 430.89 7 158.36 640.26 5.06 13.2 474.42 
13i 444.12 5 124.22 601.82 5.7 12.5 444.12 
13j 368.21 5 124.22 507.25 4.35 10.6 368.21 
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Table 8: Correlation matrix of descriptor values 
Variables Q_VSA_HYD a_acc TPSA vdw_vol logP(o/w) SMR vdw_area 
Q_VSA_HYD 1.000 0.496 0.708 0.909 0.842 0.890 0.909 
a_acc 0.496 1.000 0.874 0.479 0.338 0.414 0.604 
TPSA 0.708 0.874 1.000 0.740 0.557 0.697 0.824 
vdw_vol 0.909 0.479 0.740 1.000 0.836 0.995 0.986 
logP(o/w) 0.842 0.338 0.557 0.836 1.000 0.843 0.822 
SMR 0.890 0.414 0.697 0.995 0.843 1.000 0.970 
vdw_area 0.909 0.604 0.824 0.986 0.822 0.970 1.000 
Figure 11: Heat map of correlation matrix of descriptor values 
Figure 12: Histogram distribution of target compounds according to Q_VSA_HYD values 
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Docking simulations 
Molecular docking studies are one of the 
main challenging aspects in the computer 
drug discovery processes. Docking analysis 
was applied for the potent compounds of the 
two series 4a-c and 7c for discovery of their 
mode of action. The process was done with 
the selective pharmacological target protein 
which regulates the cell proliferation at vari-
ous stages in breast and colon cancers. The in-
verse docking process has demonstrated that 
the proteins, Caspase-3 and EGFR have sig-
nificant docking score and binding affinity 
with corresponding compounds. The H-bond 
profile and binding affinity of compounds to-
wards active site amino acids of target pro-
teins were presented in Figures14 and 15. Ac-
cording to the results of compounds docking, 
they behaved as the original reference drugs 
do in the protein pocket. In case of caspase-3 
enzyme, all three potent compounds 4a-c 
formed stable hydrogen bonding system with 
the targets through the triad fragments in their 
structures, NH2-NH2-CN by the correspond-
ing amino acid residues Gly122, Ser120, 
Arg207, and Gln161. In addition, a hydro-
phobic contact with the rest of the pocket had 
occurred by the substituted phenyl ring. For 
EGFR target, the triad fragment system NH2-
NH2-CN also formed stable hydrogen bonds 
with the amino acid Met769, Gln767, 
Thr766, and Thr830 residues in the pocket. 
As well, arene aromatic interaction occurred 
with target residues through the substituted 
phenyl ring. In contrast to compound 7c, the 
amino group is so far from the rest of triad 
fragment system and hence lost the hydrogen 
bonding interaction; this is what made the ac-
tivity different. This interaction analysis is 
consistent with the reference drug interaction 
and what was published (Ruddarraju et al., 
2016). The behavior of these ligands against 
target proteins explained the importance of 
the presence of amino group to be neighbor to 
the hydroxyl group and the size substitution 
on phenyl ring. The anti-cancer activity of the 
novel synthesized compounds and their mo-
lecular interactions with various therapeutic 
targets related to cancer in the docking study 
proved that more number of pharmacophore 
features (H-bonds acceptors, H-bond acceptor 
and Donors, Aromatic centers) in the sub-
structures of chromene nucleus played a cru-
cial role in the formation of H-bonding and 
aromatic interactions with functional groups 
of inhibitor binding site residues leading to 
down regulation of cancer cell signaling or 
apoptotic activation. 
 
CONCLUSIONS 
New series of chromene compounds have 
been prepared via multi-components reaction 
of 3-amino-2-naphthol with malononitrile 
and aromatic aldehydes in the presence of pi-
peridine. The structures of the obtained com-
pounds were confirmed using FT-IR, NMR 
and mass spectroscopy. Using the same meth-
odology, a novel series of chromene contain-
ing azo chromophores was successfully syn-
thesized via two steps’ reaction. First, prepar-
ing the azo dye derivatives followed by the 
established methodology of the multi-compo-
nents chromene approach. UV-vis of the new 
materials shows that the incorporation of the 
chromene moieties didn’t alter their λmax val-
ues. The new compounds have been evaluated 
for their antimicrobial and antiproliferative 
activities. Several of the target compounds 
showed potent antibacterial and antifungal ef-
fects towards some strains. In addition, they 
displayed more potency as anticancer agents 
with IC50 values in low micromolar concen-
trations. Certain studies have been employed 
to clarify their mechanisms and proved that 
these series could play their rule through the 
apoptotic effect by activation of caspases. As 
well, SAR analyses were discussed and ex-
plained by application of different computa-
tional methods. 
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Figure 14: Molecular interactions of the target compounds 4a, 4b, 4c, 7c, and reference ligand with 
active site of target protein caspase-3 enzyme 
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Figure 15: Molecular interactions of the target compounds 4a, 4b, 4c, 7c, and reference ligand with 
active site of target protein EGFR enzyme 
 
 
 
 
 
EXCLI Journal 2017;16:868-902 – ISSN 1611-2156 
Received: April, 13, 2017, accepted: June 09, 2017, published: June 19, 2017 
 
 
899 
Declaration of interest 
The authors declare no conflicts of inter-
est. 
 
REFERENCES 
Abd-El-Aziz AS, Afifi TH. Novel azo disperse dyes 
derived from aminothiophenes: Synthesis and UV–vis-
ible studies. Dyes and Pigments. 2006;70:8-17. 
Abd-El-Aziz AS, Alsaggaf AT, Okasha RM, Ahmed 
HEA, Bissessur R, Abdelghani AA, et al. Antimicro-
bial and antitumor screening of fluorescent 5,7-dihy-
droxy-4-propyl-2H-chromen-2-one derivatives with 
docking studies. Chemistry Select. 2016;1:5025-33. 
Afifi TH. One-bath dyeing of polyester/wool blend us-
ing azodyes derived from 2-aminothiophenes. Adv 
Colour Sci Technol. 2003;6:63-72. 
Ahmed HEA, Abdel-Salam HA, Shaker MA. Synthe-
sis, characterization, molecular modeling, and poten-
tial antimicrobial and anticancer activities of novel 2-
aminoisoindoline-1,3-dione derivatives. Bioorg Chem. 
2016;66:1-11. 
Ali KA, Abdelhafez NAA, Ragab EA, Ibrahim AA, 
Amr AE. Design and synthesis of novel fused hetero-
cycles using 4-chromanone as synthon. Russ J Gen 
Chem. 2015;85:2853-60. 
Alley MC, Scudiero DA, Monks A, Hursey ML, Czer-
winski MJ, Fine DL, et al. Feasibility of drug screening 
with panels of human tumor cell lines using a micro-
culture tetrazolium assay. Cancer Res. 1988;48:589-
601. 
Atta-ur-Rahman MIC, Thomsen WJ. Bioassay tech-
niques for drug development bioassay techniques for 
drug development. Amsterdam: Harwood Academic 
Publishers, 2001. 
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat 
TN, Weissig H, et al. The Protein Data Bank. Nucleic 
Acids Res. 2000;28:235-42. 
Boominathan M, Nagaraj M, Muthusubramanian S, 
Krishnakumar RV. Efficient atom economical one-pot 
multicomponent synthesis of densely functionalized 
4H-chromene derivatives. Tetrahedron. 2011;67: 
6057-64. 
Bush K. Antibacterial drug discovery in the 21st cen-
tury. Clin Microbiol Infect. 2004;10(Suppl. 4):10-7. 
Cai SX, Drewe J, Kasibhatla S. A chemical genetics 
approach for the discovery of apoptosis inducers: from 
phenotypic cell based HTS assay and structure-activity 
relationship studies, to identification of potential anti-
cancer agents and molecular targets. Curr Med Chem. 
2006;13:2627-44. 
Cappuccino JG, Sherman N. Microbiology: a labora-
tory manual. 5th ed. SanFrancisco, CA: Benjamin-
Cummings Publ Co., 1999. 
Cheng JF, Ishikawa A, Ono Y, Arrhenius T, Nadzan A. 
Novel chromene derivatives as TNF-alpha inhibitors. 
Bioorg Med Chem Lett. 2003;13:3647-50. 
Coates A, Hu Y, Bax R, Page C. The future challenges 
facing the development of new antimicrobial drugs. 
Nat Rev Drug Discov. 2002;1:895-910. 
Devakaram R, Black DS, Choomuenwai V, Davis RA, 
Kumar N. Synthesis and antiplasmodial evaluation of 
novel chromeno[2,3-b]chromene derivatives. Bioorg 
Med Chem. 2012;20:1527-34. 
Devasahayam G, Scheld WM, Hoffman PS. Newer an-
tibacterial drugs for a new century. Expert Opin Inves-
tig Drugs. 2010;19:215-34. 
Du L, Mahdi F, Jekabsons MB, Nagle DG, Zhou YD. 
Natural and semisynthetic mammea-type isoprenylated 
dihydroxycoumarins uncouple cellular respiration. J 
Nat Prod. 2011;74:240-8. 
El-Agrody AME-H, Abd El-Latif MS, Fakery AH,  El-
Sayed ESM, El-Ghareah KA. Synthesis of pyrano [2,3-
d]pyrimidine and pyrano[3,2-e] [1,2,4]triazolo[2,3-
c]pyrimidine derivatives with promising antibacterial 
activity. Acta Pharm. 2000;50:111-20. 
Elinson MN, Ilovaisky AI, Merkulova VM, Belyakov 
PA, Chizhov AO, Nikishin GI. Solvent-free cascade 
reaction: direct multicomponent assembling of 2-
amino-4H-chromene scaffold from salicylaldehyde, 
malononitrile or cyanoacetate and nitroalkanes. Tetra-
hedron. 2010;66:4043-8. 
Gangadevi V, Muthumary M. Preliminary studies on 
cytotoxic effect of fungal taxol on cancer cell lines. Afr 
J Biotechnol. 2007;6:1382-6. 
Gellert M, O'Dea MH, Itoh T, Tomizawa J. Novobi-
ocin and coumermycin inhibit DNA supercoiling cata-
lyzed by DNA gyrase. Proc Natl Acad Sci U S A. 
1976;73:4474-8. 
EXCLI Journal 2017;16:868-902 – ISSN 1611-2156 
Received: April, 13, 2017, accepted: June 09, 2017, published: June 19, 2017 
 
 
900 
Gourdeau H, Leblond L ,Hamelin B, Desputeau C, 
Dong K, Kianicka I, et al. Antivascular and antitumor 
evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-
phenyl)-3-cyano-4H-chromenes, a novel series of anti-
cancer agents. Mol Cancer Ther. 2004;3:1375-84. 
Higginson IJ, Costantini M. Dying with cancer, living 
well with advanced cancer. Eur J Cancer. 2008;44: 
1414-24. 
Hogg RV, Tanis E, Zimmerman D. Probability and sta-
tistical inference. 9th ed. New York: Macmillan Pub-
lishing, 1993. 
Iriti M, Faoro F. Bioactive chemicals and health bene-
fits of grapevine products. In: Watson RR, Preedy VR 
(eds.): Bioactive foods in promoting health: fruits and 
vegetables (pp 581-620). San Diego, CA: Academic 
Press, 2010. 
Isakoff SJ. Triple-negative breast cancer: role of spe-
cific chemotherapy agents. Cancer J. 2010;16:53-61. 
Jain N, Xu J, Kanojia RM, Du F, Jian-Zhong G, Pacia 
E, et al. Identification and structure-activity relation-
ships of chromene-derived selective estrogen receptor 
modulators for treatment of postmenopausal symp-
toms. J Med Chem. 2009;52:7544-69. 
Juan D, Pérez-Vizcaíno F, Jiménez J, Tamargo J, Zar-
zuelo A. Flavonoids and cardiovascular diseases. In: 
Atta-ur-Rahman (ed.): Bioactive natural products, Part 
F (pp 565-605). Amsterdam: Elsevier, 2001. (Studies 
in Natural Products Chemistry, Vol. 25, Part F). 
Kamdar NR, Haveliwala DD, Mistry PT, Patel SK. 
Synthesis and evaluation of in vitro antitubercular ac-
tivity and antimicrobial activity of some novel 4H-
chromeno[2,3-d]pyrimidine via 2-amino-4-phenyl-
4H-chromene-3-carbonitriles. Med Chem Res. 2010; 
20:854-64. 
Kemnitzer W, Drewe J, Jiang S, Zhang H, Wang Y, 
Zhao J, et al. Discovery of 4-aryl-4H-chromenes as a 
new series of apoptosis inducers using a cell- and 
caspase-based high-throughput screening assay. 1. 
Structure-activity relationships of the 4-aryl group. J 
Med Chem. 2004;47:6299-310. 
Kemnitzer W, Kasibhatla S, Jiang S, Zhang H, Zhao J, 
Jia S, et al. Discovery of 4-aryl-4H-chromenes as a new 
series of apoptosis inducers using a cell- and caspase-
based high-throughput screening assay. 2. Structure-
activity relationships of the 7- and 5-, 6-, 8-positions. 
Bioorg Med Chem Lett. 2005;15:4745-51. 
Kemnitzer W, Drewe J, Jiang S, Zhang H, Zhao J, 
Crogan-Grundy C, et al. Discovery of 4-aryl-4H-
chromenes as a new series of apoptosis inducers using 
a cell- and caspase-based high-throughput screening 
assay. 3. Structure-activity relationships of fused rings 
at the 7,8-positions. J Med Chem. 2007;50:2858-64. 
Kemnitzer W, Drewe J, Jiang S, Zhang H, Crogan-
Grundy C, Labreque D, et al. Discovery of 4-aryl-4H-
chromenes as a new series of apoptosis inducers using 
a cell- and caspase-based high throughput screening as-
say. 4. Structure-activity relationships of N-alkyl sub-
stituted pyrrole fused at the 7,8-positions. J Med Chem. 
2008;51:417-23. 
Kirilmis C, Ahmedzade M, Servi S, Koca M, Kizirgil 
A, Kazaz C. Synthesis and antimicrobial activity of 
some novel derivatives of benzofuran: Part 2. The syn-
thesis and antimicrobial activity of some novel 1-(1-
benzofuran-2-yl)-2-mesitylethanone derivatives. Eur J 
Med Chem. 2008;43:300-8. 
Klancnik A, Piskernik S, Jersek B, Mozina SS. Evalu-
ation of diffusion and dilution methods to determine 
the antibacterial activity of plant extracts. J Microbiol 
Methods. 2010;81:121-6. 
Kumar D, Reddy VB, Sharad S, Dube U, Kapur S. A 
facile one-pot green synthesis and antibacterial activity 
of 2-amino-4H-pyrans and 2-amino-5-oxo-5,6,7,8-tet-
rahydro-4H-chromenes. Eur J Med Chem. 2009;44: 
3805-9. 
Makarem S, Mohammadi AA, Fakhari AR. A multi-
component electro-organic synthesis of 2-amino-4H-
chromenes. Tetrahedron Lett. 2008;49:7194-6. 
Mehrabi H, Kazemi-Mireki M. CuO nanoparticles: An 
efficient and recyclable nanocatalyst for the rapid and 
green synthesis of 3,4-dihydropyrano[c]chromenes. 
Chin Chem Lett. 2011;22:1419-22. 
Mladenovic M, Mihailovic M, Bogojevic D, Matic S, 
Niciforovic N, Mihailovic V, et al. In vitro antioxidant 
activity of selected 4-hydroxy-chromene-2-one deriva-
tives-SAR, QSAR and DFT studies. Int J Mol Sci. 
2011;12:2822-41. 
Molecular Operating Environment (MOE), Chemical 
Computing Group, Quebec, Canada. 2012; 
http://www.chemcomp.com. Accessed on 30/02/2013.  
Mori J, Iwashima M, Takeuchi M, Saito H. A synthetic 
study on antiviral and antioxidative chromene deriva-
tive. Chem Pharm Bull (Tokyo). 2006;54:391-6. 
EXCLI Journal 2017;16:868-902 – ISSN 1611-2156 
Received: April, 13, 2017, accepted: June 09, 2017, published: June 19, 2017 
 
 
901 
Mosmann T. Rapid colorimetric assay for cellular 
growth and survival: application to proliferation and 
cytotoxicity assays. J Immunol Methods. 1983;65:55-
63. 
Murthy SN, Madhav B, Reddy VP, Nageswar YVD. 
One-pot synthesis of 2-amino-4H-chromen-4-yl phos-
phonate derivatives using β-cyclodextrin as reusable 
catalyst in water. Tetrahedron Lett. 2010;51:3649-53. 
Nicolaou KC, Pfefferkorn JA, Roecker AJ, Cao GQ, 
Barluenga S, Mitchell HJ. Natural product-like combi-
natorial libraries based on privileged structures. 1. 
General principles and solid-phase synthesis of ben-
zopyrans. J Am Chem Soc. 2000;122:9939-53. 
Park JH, Lee SU, Kim SH, Shin SY, Lee JY, Shin CG, 
et al. Chromone and chromanone derivatives as strand 
transfer inhibitors of HIV-1 integrase. Arch Pharm 
Res. 2008;31:1-5. 
Patil KR, Mohapatra P, Patel HM, Goyal SN, Ojha S, 
Kundu CN, et al. Pentacyclic triterpenoids inhibit 
ikkbeta mediated activation of NF-kappaB pathway: in 
silico and in vitro evidences. PLoS One. 2015;10: 
e0125709. 
Pritchard JR, Bruno PM, Gilbert LA, Capron KL, 
Lauffenburger DA, Hemann MT. Defining principles 
of combination drug mechanisms of action. Proc Natl 
Acad Sci USA. 2013;110:E170-9. 
Ren Q, Siau WY, Du Z, Zhang K, Wang J. Expeditious 
assembly of a 2-amino-4H-chromene skeleton by using 
an enantioselective Mannich intramolecular ring cy-
clization-tautomerization cascade sequence. Chemis-
try. 2011;17:7781-5. 
Ruddarraju RR, Murugulla AC, Kotla R, Chandra 
Babu Tirumalasetty M, Wudayagiri R, Donthabakthuni 
S, et al. Design, synthesis, anticancer, antimicrobial ac-
tivities and molecular docking studies of theophylline 
containing acetylenes and theophylline containing 
1,2,3-triazoles with variant nucleoside derivatives. Eur 
J Med Chem. 2016;123:379-96. 
Sabry NM, Mohamed HM, Khattab ESAEH, Motlaq S. 
S, El-Agrody AM. Synthesis of 4H-chromene, couma-
rin, 12H-chromeno[2,3-d]pyrimidine derivatives and 
some of their antimicrobial and cytotoxicity activities. 
Eur J Med Chem. 2011;46:765-72. 
Safari J, Javadian L. Ultrasound assisted the green syn-
thesis of 2-amino-4H-chromene derivatives catalyzed 
by Fe3O4-functionalized nanoparticles with chitosan as 
a novel and reusable magnetic catalyst. Ultrason Sono-
chem. 2015;22:341-8. 
Sangani CB, Shah NM, Patel MP, Patel RG. Micro-
wave-assisted synthesis of novel 4H-chromene deriva-
tives bearing phenoxypyrazole and their antimicrobial 
activity assessment. J Serb Chem Soc. 2012;77:1165-
74. 
Sangani CB, Shah NM, Patel MP, Patel RG. Micro-
wave-assisted synthesis of novel 4H-chromene deriva-
tives bearing 2-aryloxyquinoline and their antimicro-
bial activity assessment. Med Chem Res. 2013;22: 
3831-42. 
Settimo AD, Settimo FD, Marini AM, Primofiore G, 
Salerno S, Viola G, et al. Synthesis, DNA binding and 
in vitro antiproliferative activity of purinoquinazoline, 
pyridopyrimidopurine and pyridopyrimidobenzimid-
azole derivatives as potential antitumor agents. Eur J 
Med Chem. 1998;33:685-96. 
Shafiei-Haghighi MH-SaS. Multi-component synthe-
sis of 2-amino-4H-chromenes catalyzed by nano ZnO 
in water. Collect Czech Chem Commun. 2011;76: 
1285-98. 
Shawali AS, Samy NA. Functionalized formazans: A 
review on recent progress in their pharmacological ac-
tivities. J Adv Res. 2015;6:241-54. 
Smania JA, Monache FD, Smania EFA, Cuneo RS. 
Antibacterial activity of steroidal compounds isolated 
from Ganoderma applanatum (Pers.) Pat. (Aphyllopho-
romycetideae) fruit body. Int J Med Mushrooms. 1999; 
1:325-30. 
Sondhi SM, Singh J, Rani R, Gupta PP, Agrawal SK, 
Saxena AK. Synthesis, anti-inflammatory and anti-
cancer activity evaluation of some novel acridine de-
rivatives. Eur J Med Chem. 2010;45:555-63. 
Stepanchikova AV, Lagunin AA, Filimonov DA, 
Poroikov VV. Prediction of biological activity spectra 
for substances: evaluation on the diverse sets of drug-
like structures. Curr Med Chem. 2003;10:225-33. 
Thareja S, Verma A, Kalra A, Gosain S, Rewatkar PV, 
Kokil GR. Novel chromeneimidazole derivatives as 
antifungal compounds: synthesis and in vitro evalua-
tion. Acta Pol Pharm. 2010;67:423-7. 
Trinchieri G. Cancer immunity: lessons from infec-
tious diseases. J Infect Dis. 2015;212(Suppl 1):S67-73. 
Vanden Berghe DA, Vlietinck AJ. Screening methods 
for antibacterial and antiviral agents from higher 
plants. In: Dey PM, Harbone JD (eds.): Methods in 
plant biochemistry (pp 47-69). London: Academic 
Press, 1991. 
EXCLI Journal 2017;16:868-902 – ISSN 1611-2156 
Received: April, 13, 2017, accepted: June 09, 2017, published: June 19, 2017 
 
 
902 
Varmus H. The new era in cancer research. Science. 
2006;312:1162-5. 
Voskressensky LG, Festa AA, Varlamov AV. Domino 
reactions based on knoevenegel condensation in the 
synthesis of heterocyclic compounds, recent advances. 
Tetrahedron. 2014;70:551-72. 
Wainwright M. Dyes in the development of drugs and 
pharmaceuticals. Dyes and Pigments. 2008;76:582-9. 
Widelski J, Popova M, Graikou K, Glowniak K, Chi-
nou I. Coumarins from Angelica lucida L. - antibacte-
rial activities. Molecules. 2009;14:2729-34. 
Yadav JS, Reddy BVS, Gupta MK, Prathap I, Pandey 
SK. Amberlyst A-21®: An efficient, cost-effective and 
recyclable catalyst for the synthesis of substituted 4H-
chromenes. Catal Commun. 2007;8:2208-11. 
Zheng L-W, Zhu J, Zhao B-X, Huang Y-H, Ding J, 
Miao J-Y. Synthesis, crystal structure and biological 
evaluation of novel 2-(5-(hydroxymethyl)-3-phenyl-
1H-pyrazol-1-yl)-1-phenylethanol derivatives. Eur J 
Med Chem. 2010;45:5792-9. 
 
